###begin article-title 0
###xml 38 43 38 39 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#945;</bold>
###xml 50 54 46 47 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#946;</bold>
###xml 109 116 102 109 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
C-Terminal regions of topoisomerase IIalpha and IIbeta determine isoform-specific functioning of the enzymes in vivo
###end article-title 0
###begin p 1
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/2.0/uk/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
###end p 1
###begin p 2
###xml 580 585 <span type="species:ncbi:9606">human</span>
###xml 736 741 <span type="species:ncbi:9606">human</span>
###xml 1273 1278 <span type="species:ncbi:9606">human</span>
Topoisomerase II removes supercoils and catenanes generated during DNA metabolic processes such as transcription and replication. Vertebrate cells express two genetically distinct isoforms (alpha and beta) with similar structures and biochemical activities but different biological roles. Topoisomerase IIalpha is essential for cell proliferation, whereas topoisomerase IIbeta is required only for aspects of nerve growth and brain development. To identify the structural features responsible for these differences, we exchanged the divergent C-terminal regions (CTRs) of the two human isoforms (alpha 1173-1531 and beta 1186-1621) and tested the resulting hybrids for complementation of a conditional topoisomerase IIalpha knockout in human cells. Proliferation was fully supported by all enzymes bearing the alpha CTR. The alpha CTR also promoted chromosome binding of both enzyme cores, and was by itself chromosome-bound, suggesting a role in enzyme targeting during mitosis. In contrast, enzymes bearing the beta CTR supported proliferation only rarely and when expressed at unusually high levels. A similar analysis of the divergent N-terminal regions (alpha 1-27 and beta 1-43) revealed no role in isoform-specific functions. Our results show that it is the CTRs of human topoisomerase II that determine their isoform-specific functions in proliferating cells. They also indicate persistence of some functional redundancy between the two isoforms.
###end p 2
###begin title 3
INTRODUCTION
###end title 3
###begin p 4
###xml 238 241 238 241 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B1 B2 B3">1&#8211;3</xref>
###xml 362 363 362 363 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B4">4</xref>
###xml 579 580 579 580 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B5">5</xref>
###xml 581 582 581 582 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B6">6</xref>
###xml 704 705 704 705 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B7">7</xref>
###xml 706 707 706 707 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B8">8</xref>
###xml 810 811 810 811 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B9">9</xref>
###xml 973 978 966 971 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B10 B11 B12 B13 B14">10&#8211;14</xref>
###xml 292 297 <span type="species:ncbi:9606">human</span>
###xml 793 799 <span type="species:ncbi:9606">infant</span>
The enzyme topoisomerase II is responsible for resolving catenanes and supercoils in chromosomal DNA that are generated during DNA metabolic processes. It plays an essential role in condensation and segregation of chromosomes at mitosis (1-3). Topoisomerase II is of considerable interest to human medicine, because it is an important target for cancer therapy (4). It is also suspected that topoisomerase II can be converted into a potent DNA toxin by minor (and as such repairable) DNA lesions frequently induced by environmental factors (e.g. UV radiation, oxidative stress) (5,6). Moreover, certain nutritional constituents (e.g. flavonoids) are known to disturb the enzyme's normal catalytic cycle (7,8), which is thought to contribute to translocations within the MLL-locus that trigger infant leukemia (9). These adverse properties of topoisomerase II could be the ultimate reason why vertebrates maintain two genetically distinct isoforms (denoted alpha and beta) (10-14), while lower eukaryotes have only one.
###end p 4
###begin p 5
###xml 254 256 247 249 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B15">15</xref>
###xml 257 259 250 252 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B16">16</xref>
###xml 285 293 278 286 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 406 408 395 397 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B17">17</xref>
###xml 467 472 456 461 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B18 B19 B20 B21">18&#8211;21</xref>
###xml 618 620 603 605 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B22">22</xref>
###xml 621 623 606 608 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B23">23</xref>
###xml 735 737 720 722 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B24">24</xref>
###xml 866 868 847 849 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B25">25</xref>
###xml 869 871 850 852 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B26">26</xref>
###xml 980 982 957 959 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B27">27</xref>
###xml 1175 1180 1149 1154 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B28 B29 B30">28&#8211;30</xref>
###xml 603 608 <span type="species:ncbi:4932">yeast</span>
###xml 740 745 <span type="species:ncbi:9606">Human</span>
###xml 895 900 <span type="species:ncbi:10090">mouse</span>
The divergence of vertebrate topoisomerase II into alpha and beta isoforms remains enigmatic, because the two enzymes are very similar in structure and function. They share a high degree of overall sequence homology with 68% identity and 86% similarity (15,16). So far, the only major in vitro difference between the two isoforms is a preferential relaxation of positive supercoils by the IIalpha isoform (17), whereas other basic catalytic aspects are very similar (18-21). Moreover, they have the same capacity for complementing essential topoisomerase II functions in temperature-sensitive Deltatop2 yeast mutants (22,23). Despite these similarities, the two isozymes apparently play different biological roles in vertebrate cells (24). Human cell lines lacking the alpha isoform encounter serious problems at mitosis because chromosome segregation is deficient (25,26). For similar reasons, mouse embryos lacking the TOP2alpha gene, fail to develop beyond the 4-8-cell stage (27). In contrast, mammalian cell lines lacking topoisomerase IIbeta pass normally through mitosis, and their most prominent phenotype is a decreased sensitivity towards topoisomerase II poisons (28-30).
###end p 5
###begin p 6
###xml 413 415 403 405 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B31">31</xref>
###xml 432 434 422 424 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B32">32</xref>
###xml 611 613 598 600 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B33">33</xref>
###xml 932 934 916 918 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B34">34</xref>
###xml 1066 1068 1047 1049 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B35">35</xref>
###xml 1175 1177 1156 1158 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B36">36</xref>
###xml 1274 1276 1251 1253 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B37">37</xref>
###xml 1277 1279 1254 1256 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B38">38</xref>
###xml 298 302 <span type="species:ncbi:10090">mice</span>
These findings indicate that all essential topoisomerase II functions in cell-cycle-related events, such as DNA replication and sister chromatid segregation, can be performed by the alpha isozyme, while the beta isozyme does not play an essential role in proliferating cells. And yet, TOP2beta -/- mice are not viable. They suffocate shortly after birth due to developmental defects of motor and sensory neurons (31) and the brain (32). These defects most likely reflect a requirement of topoisomerase IIbeta activity in regulating the expression of genes important at later stages of neuronal differentiation (33). This view has convincingly been confirmed by the recent finding that the beta isoform plays an important role in the regulation of gene transcription, in as much as it introduces double-strand breaks at promoter regions of several genes, which are required for the proper signal-dependent activation of these genes (34). In this respect, it is of interest that topoisomerase IIbeta is constitutively expressed in all cells of the mammalian organism (35), probably because expression is driven by a promoter with features characteristic of housekeeping genes (36), whereas expression of topoisomerase IIalpha is repressed as soon as cells stop proliferating (37,38). Therefore, the beta isoenzyme is the only type II topoisomerase available in quiescent cells. In synopsis, the data available clearly suggest that the two isoforms have different biological functions in vertebrate organisms.
###end p 6
###begin p 7
###xml 758 760 737 739 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B15">15</xref>
###xml 761 763 740 742 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B16">16</xref>
###xml 764 769 743 748 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B39 B40 B41 B42">39&#8211;42</xref>
###xml 1050 1052 1022 1024 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B16">16</xref>
###xml 1335 1337 1293 1295 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B43">43</xref>
###xml 1338 1340 1296 1298 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B44">44</xref>
###xml 1430 1432 1384 1386 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B26">26</xref>
###xml 1098 1103 <span type="species:ncbi:9606">human</span>
###xml 1265 1270 <span type="species:ncbi:9606">human</span>
###xml 1417 1422 <span type="species:ncbi:9606">human</span>
Here, we address the question of precisely which features render topoisomerase IIalpha essential for cell proliferation, and conversely, lack of which features prevents topoisomerase IIbeta from adopting these functions. We have approached this problem by identifying those parts of topoisomerase IIalpha and IIbeta that are responsible for isoform-specific functioning inside the living mammalian cell. We started from the assumption that those portions of the enzymes that are most divergent between alpha and beta forms would be most likely to mediate isoform-specific functions. Sequence comparisons, limited proteolysis experiments and crystallographic studies suggest that topoisomerase II is composed of three major structural and functional domains (15,16,39-42). With the exception of brief stretches at the N-terminal ends (first 27 or 43 amino acids of alpha and beta, respectively), the ATPase and the central breakage/reunion domains are similar between the two isoforms, whereas the C-terminal regions differ both in size and sequence (16). Thus, divergent and homologous portions of human topoisomerase IIalpha and IIbeta were combined in a varied manner to form alpha/beta-chimeric enzymes that were tested for unique, isoform-specific functions in human cells, most notably for localization of the enzymes at mitosis (43,44) and for complementation of a conditional topoisomerase IIalpha knockout in human cells (26).
###end p 7
###begin title 8
MATERIALS AND METHODS
###end title 8
###begin title 9
Alignment, plasmid construction, cell culture and live cell imaging
###end title 9
###begin p 10
###xml 173 175 166 168 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B45">45</xref>
###xml 292 300 278 286 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F1">Figure 1</xref>
###xml 345 347 331 333 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B46">46</xref>
###xml 516 518 502 504 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B47">47</xref>
###xml 631 633 610 612 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B44">44</xref>
###xml 1000 1002 965 967 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B47">47</xref>
###xml 1367 1369 1328 1330 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;1</sup>
###xml 1993 1994 1944 1945 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 2349 2351 2292 2294 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B26">26</xref>
###xml 2608 2610 2543 2545 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;1</sup>
###xml 2643 2645 2574 2576 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;1</sup>
###xml 2819 2820 2738 2739 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
###xml 2829 2831 2748 2750 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;1</sup>
###xml 2995 3004 2914 2923 <label xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 1.</label>
###xml 3005 3006 2924 2925 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 3628 3629 3540 3541 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
###xml 3869 3873 3757 3761 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B1 B2 B3 B4 B5 B6 B7 B8 B9 B10 B11 B12 B13 B14 B15 B16 B17 B18 B19 B20 B21 B22 B23 B24 B25 B26 B27 B28 B29 B30 B31 B32 B33 B34 B35 B36 B37 B38 B39 B40 B41 B42 B43">1&#8211;43</xref>
###xml 3951 3955 3824 3828 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B1 B2 B3 B4 B5 B6 B7 B8 B9 B10 B11 B12 B13 B14 B15 B16 B17 B18 B19 B20 B21 B22 B23 B24 B25 B26 B27">1&#8211;27</xref>
###xml 3004 4273 2923 4093 <p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" textid="11">(<bold>A</bold>) Comparison of human topoisomerase II&#945; and II&#946;. Amino acid sequence alignment of the two isoforms indicates two regions with low and one with high sequence homology. Short stretches of the N-terminal ends (denoted &#8216;NTS&#8217;) and the CTR have highly divergent sequences, whereas most of the ATPase domains and the catalytic cores (denoted &#8216;Conserved enzyme core&#8217;) are similar. Y805 and Y821 are the active site tyrosines. Numbers indicate last residues of the respective regions selected for fission/fusion and truncation of enzyme variants. Amino acid identities and similarities for each region are indicated below. (<bold>B</bold>) Schematic synopsis of the constructs studied. All constructs were fused to YFP at their C-terminal ends; topo II&#945;, topo II&#946;: full-length human topoisomerases II&#945; and II&#946;; &#946; NTS/&#945;: chimeric human topoisomerase II&#946; (<xref ref-type="bibr" rid="B1 B2 B3 B4 B5 B6 B7 B8 B9 B10 B11 B12 B13 B14 B15 B16 B17 B18 B19 B20 B21 B22 B23 B24 B25 B26 B27 B28 B29 B30 B31 B32 B33 B34 B35 B36 B37 B38 B39 B40 B41 B42 B43">1&#8211;43</xref>) &#8211;&gt; II&#945; (28&#8211;1531); &#945; NTS/&#946;: chimeric human topoisomerase II&#945; (<xref ref-type="bibr" rid="B1 B2 B3 B4 B5 B6 B7 B8 B9 B10 B11 B12 B13 B14 B15 B16 B17 B18 B19 B20 B21 B22 B23 B24 B25 B26 B27">1&#8211;27</xref>) &#8722;&gt; II&#946; (44&#8211;1621); &#945;/&#946; CTR: chimeric human topoisomerase II&#945; (1&#8211;1172) &#8722;&gt; II&#946; (1186&#8211;1621); &#946;/&#945; CTR: chimeric human topoisomerase II&#946; (1&#8211;1185) &#8722;&gt; II&#945; (1173&#8211;1531); &#945; CTR: truncated human topoisomerase II&#945; (&#916;1&#8211;1172); &#946; CTR: truncated human topoisomerase II&#946; (&#916;1&#8211;1185).</p>
###xml 3004 4273 2923 4093 <caption xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><p textid="11">(<bold>A</bold>) Comparison of human topoisomerase II&#945; and II&#946;. Amino acid sequence alignment of the two isoforms indicates two regions with low and one with high sequence homology. Short stretches of the N-terminal ends (denoted &#8216;NTS&#8217;) and the CTR have highly divergent sequences, whereas most of the ATPase domains and the catalytic cores (denoted &#8216;Conserved enzyme core&#8217;) are similar. Y805 and Y821 are the active site tyrosines. Numbers indicate last residues of the respective regions selected for fission/fusion and truncation of enzyme variants. Amino acid identities and similarities for each region are indicated below. (<bold>B</bold>) Schematic synopsis of the constructs studied. All constructs were fused to YFP at their C-terminal ends; topo II&#945;, topo II&#946;: full-length human topoisomerases II&#945; and II&#946;; &#946; NTS/&#945;: chimeric human topoisomerase II&#946; (<xref ref-type="bibr" rid="B1 B2 B3 B4 B5 B6 B7 B8 B9 B10 B11 B12 B13 B14 B15 B16 B17 B18 B19 B20 B21 B22 B23 B24 B25 B26 B27 B28 B29 B30 B31 B32 B33 B34 B35 B36 B37 B38 B39 B40 B41 B42 B43">1&#8211;43</xref>) &#8211;&gt; II&#945; (28&#8211;1531); &#945; NTS/&#946;: chimeric human topoisomerase II&#945; (<xref ref-type="bibr" rid="B1 B2 B3 B4 B5 B6 B7 B8 B9 B10 B11 B12 B13 B14 B15 B16 B17 B18 B19 B20 B21 B22 B23 B24 B25 B26 B27">1&#8211;27</xref>) &#8722;&gt; II&#946; (44&#8211;1621); &#945;/&#946; CTR: chimeric human topoisomerase II&#945; (1&#8211;1172) &#8722;&gt; II&#946; (1186&#8211;1621); &#946;/&#945; CTR: chimeric human topoisomerase II&#946; (1&#8211;1185) &#8722;&gt; II&#945; (1173&#8211;1531); &#945; CTR: truncated human topoisomerase II&#945; (&#916;1&#8211;1172); &#946; CTR: truncated human topoisomerase II&#946; (&#916;1&#8211;1185).</p></caption>
###xml 4273 4273 4093 4093 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xlink:href="gkm102f1"/>
###xml 2995 4273 2914 4093 <fig xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="F1" position="float"><label>Figure 1.</label><caption><p textid="11">(<bold>A</bold>) Comparison of human topoisomerase II&#945; and II&#946;. Amino acid sequence alignment of the two isoforms indicates two regions with low and one with high sequence homology. Short stretches of the N-terminal ends (denoted &#8216;NTS&#8217;) and the CTR have highly divergent sequences, whereas most of the ATPase domains and the catalytic cores (denoted &#8216;Conserved enzyme core&#8217;) are similar. Y805 and Y821 are the active site tyrosines. Numbers indicate last residues of the respective regions selected for fission/fusion and truncation of enzyme variants. Amino acid identities and similarities for each region are indicated below. (<bold>B</bold>) Schematic synopsis of the constructs studied. All constructs were fused to YFP at their C-terminal ends; topo II&#945;, topo II&#946;: full-length human topoisomerases II&#945; and II&#946;; &#946; NTS/&#945;: chimeric human topoisomerase II&#946; (<xref ref-type="bibr" rid="B1 B2 B3 B4 B5 B6 B7 B8 B9 B10 B11 B12 B13 B14 B15 B16 B17 B18 B19 B20 B21 B22 B23 B24 B25 B26 B27 B28 B29 B30 B31 B32 B33 B34 B35 B36 B37 B38 B39 B40 B41 B42 B43">1&#8211;43</xref>) &#8211;&gt; II&#945; (28&#8211;1531); &#945; NTS/&#946;: chimeric human topoisomerase II&#945; (<xref ref-type="bibr" rid="B1 B2 B3 B4 B5 B6 B7 B8 B9 B10 B11 B12 B13 B14 B15 B16 B17 B18 B19 B20 B21 B22 B23 B24 B25 B26 B27">1&#8211;27</xref>) &#8722;&gt; II&#946; (44&#8211;1621); &#945;/&#946; CTR: chimeric human topoisomerase II&#945; (1&#8211;1172) &#8722;&gt; II&#946; (1186&#8211;1621); &#946;/&#945; CTR: chimeric human topoisomerase II&#946; (1&#8211;1185) &#8722;&gt; II&#945; (1173&#8211;1531); &#945; CTR: truncated human topoisomerase II&#945; (&#916;1&#8211;1172); &#946; CTR: truncated human topoisomerase II&#946; (&#916;1&#8211;1185).</p></caption><graphic xlink:href="gkm102f1"/></fig>
###xml 223 228 <span type="species:ncbi:9606">human</span>
###xml 576 581 <span type="species:ncbi:9606">human</span>
###xml 618 623 <span type="species:ncbi:9606">human</span>
###xml 1107 1112 <span type="species:ncbi:9606">Human</span>
###xml 2118 2123 <span type="species:ncbi:9606">human</span>
###xml 2244 2249 <span type="species:ncbi:9606">human</span>
###xml 3022 3027 <span type="species:ncbi:9606">human</span>
###xml 3775 3780 <span type="species:ncbi:9606">human</span>
###xml 3841 3846 <span type="species:ncbi:9606">human</span>
###xml 3922 3927 <span type="species:ncbi:9606">human</span>
###xml 4003 4008 <span type="species:ncbi:9606">human</span>
###xml 4088 4093 <span type="species:ncbi:9606">human</span>
###xml 4169 4174 <span type="species:ncbi:9606">human</span>
###xml 4232 4237 <span type="species:ncbi:9606">human</span>
We aligned amino acid sequences of topoisomerase IIalpha and IIbeta using the default settings for ClustalW v.1.83 (WWW Service at the European Bioinformatics Institute, ) (45). Exchange of defined regions between cDNAs of human topoisomerase IIalpha and IIbeta at the positions indicated in Figure 1B was accomplished by overlap-extension PCR (46). Fragments encompassing the divergent C-terminal regions alone were generated by PCR. Chimeric and truncated cDNAs were inserted into a bicistronic expression vector (47) used previously for stable expression of biofluorescent human topoisomerase IIalpha and IIbeta in human cells (44). Here, the vector was modified to provide C-terminal fusion with enhanced yellow fluorescent protein (YFP). To facilitate simultaneous visualization of topoisomerase IIalpha and IIbeta, a tricistronic expression plasmid was generated, in which topoisomerase IIalpha fused to CFP was placed in the first, and topoisomerase IIbeta fused to YFP in the second cistron (47). A vector expressing YFP alone served as a control. All new constructs were checked by DNA sequencing. Human embryonal kidney 293 cells (# DSMZ ACC 305, German Collection of Microorganisms and Cell Culture, Braunschweig, Germany) were transfected with these constructs. Stable transgenic cell clones were selected and maintained in medium containing 0.4 microg ml-1 puromycin (details see:48). Epifluorescence microscopy was done with a Zeiss Axiovert 100 inverted light microscope equipped with an on-stage heating chamber (DeltaTC3 from Bioptechs, Butler, PA, USA), a heated 63x/1.4 NA oil immersion objective system, a mercury lamp and appropriate filter sets. Confocal imaging was done with a Zeiss LSM 510 META inverted confocal laser-scanning microscope equipped with a 63x/1.4 NA oil immersion objective. To maintain a constant temperature of 37degreesC for live cell imaging, the confocal microscope was built in a ZEISS Incubator XL. Cells were cultured under the microscope in CO2-independent medium (Invitrogen, Karlsruhe, Germany). To analyze complementation of topoisomerase IIalpha function, we used human HT-1080 cells, in which both alleles of the TOP2A gene are disrupted. The cells are rescued by transgenic expression of human topoisomerase IIalpha from a tetracycline repressible construct stably integrated into the genome (26). Upon transfection of these cells (designated HTETOP) with the various chimeric constructs, complementation of topoisomerase IIalpha function was determined by comparing the number of stable cell clones obtained by selection with tetracycline (1 microg ml-1) versus puromycin (0.4 microg ml-1) (details see:26). For fluorescence activated cell sorting, cells were grown to approximately80% confluence, washed in PBS, trypsinized and resuspended in ice cold PBS at 106 cells ml-1. For each measurement, 20 000 cells were analyzed in a FACScan flow cytometer (BD bioscience) at a high flow rate setting with an Argon ion laser tuned to 488 nm. Figure 1.(A) Comparison of human topoisomerase IIalpha and IIbeta. Amino acid sequence alignment of the two isoforms indicates two regions with low and one with high sequence homology. Short stretches of the N-terminal ends (denoted 'NTS') and the CTR have highly divergent sequences, whereas most of the ATPase domains and the catalytic cores (denoted 'Conserved enzyme core') are similar. Y805 and Y821 are the active site tyrosines. Numbers indicate last residues of the respective regions selected for fission/fusion and truncation of enzyme variants. Amino acid identities and similarities for each region are indicated below. (B) Schematic synopsis of the constructs studied. All constructs were fused to YFP at their C-terminal ends; topo IIalpha, topo IIbeta: full-length human topoisomerases IIalpha and IIbeta; beta NTS/alpha: chimeric human topoisomerase IIbeta (1-43) -> IIalpha (28-1531); alpha NTS/beta: chimeric human topoisomerase IIalpha (1-27) -> IIbeta (44-1621); alpha/beta CTR: chimeric human topoisomerase IIalpha (1-1172) -> IIbeta (1186-1621); beta/alpha CTR: chimeric human topoisomerase IIbeta (1-1185) -> IIalpha (1173-1531); alpha CTR: truncated human topoisomerase IIalpha (Delta1-1172); beta CTR: truncated human topoisomerase IIbeta (Delta1-1185).
###end p 10
###begin p 11
###xml 1 2 1 2 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 624 625 617 618 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
###xml 865 869 834 838 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B1 B2 B3 B4 B5 B6 B7 B8 B9 B10 B11 B12 B13 B14 B15 B16 B17 B18 B19 B20 B21 B22 B23 B24 B25 B26 B27 B28 B29 B30 B31 B32 B33 B34 B35 B36 B37 B38 B39 B40 B41 B42 B43">1&#8211;43</xref>
###xml 947 951 901 905 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B1 B2 B3 B4 B5 B6 B7 B8 B9 B10 B11 B12 B13 B14 B15 B16 B17 B18 B19 B20 B21 B22 B23 B24 B25 B26 B27">1&#8211;27</xref>
###xml 18 23 <span type="species:ncbi:9606">human</span>
###xml 771 776 <span type="species:ncbi:9606">human</span>
###xml 837 842 <span type="species:ncbi:9606">human</span>
###xml 918 923 <span type="species:ncbi:9606">human</span>
###xml 999 1004 <span type="species:ncbi:9606">human</span>
###xml 1084 1089 <span type="species:ncbi:9606">human</span>
###xml 1165 1170 <span type="species:ncbi:9606">human</span>
###xml 1228 1233 <span type="species:ncbi:9606">human</span>
(A) Comparison of human topoisomerase IIalpha and IIbeta. Amino acid sequence alignment of the two isoforms indicates two regions with low and one with high sequence homology. Short stretches of the N-terminal ends (denoted 'NTS') and the CTR have highly divergent sequences, whereas most of the ATPase domains and the catalytic cores (denoted 'Conserved enzyme core') are similar. Y805 and Y821 are the active site tyrosines. Numbers indicate last residues of the respective regions selected for fission/fusion and truncation of enzyme variants. Amino acid identities and similarities for each region are indicated below. (B) Schematic synopsis of the constructs studied. All constructs were fused to YFP at their C-terminal ends; topo IIalpha, topo IIbeta: full-length human topoisomerases IIalpha and IIbeta; beta NTS/alpha: chimeric human topoisomerase IIbeta (1-43) -> IIalpha (28-1531); alpha NTS/beta: chimeric human topoisomerase IIalpha (1-27) -> IIbeta (44-1621); alpha/beta CTR: chimeric human topoisomerase IIalpha (1-1172) -> IIbeta (1186-1621); beta/alpha CTR: chimeric human topoisomerase IIbeta (1-1185) -> IIalpha (1173-1531); alpha CTR: truncated human topoisomerase IIalpha (Delta1-1172); beta CTR: truncated human topoisomerase IIbeta (Delta1-1185).
###end p 11
###begin title 12
Immunoblotting and band depletion assay
###end title 12
###begin p 13
###xml 105 107 105 107 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B48">48</xref>
###xml 152 153 152 153 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
###xml 467 474 467 474 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 653 654 649 650 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</sup>
###xml 1291 1293 1280 1282 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B49">49</xref>
###xml 1601 1603 1587 1589 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B49">49</xref>
###xml 1690 1692 1676 1678 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B50">50</xref>
###xml 830 835 <span type="species:ncbi:10090">mouse</span>
###xml 1000 1006 <span type="species:ncbi:9986">rabbit</span>
###xml 1087 1092 <span type="species:ncbi:9606">human</span>
###xml 1156 1162 <span type="species:ncbi:9986">rabbit</span>
###xml 1246 1251 <span type="species:ncbi:9606">human</span>
###xml 1357 1362 <span type="species:ncbi:9606">human</span>
###xml 1450 1456 <span type="species:ncbi:9986">rabbit</span>
###xml 1610 1615 <span type="species:ncbi:10090">mouse</span>
Isolation of cell nuclei and extraction of nuclear proteins (400 mM NaCl) followed published procedures (48). Whole cell lysate was prepared from 3 x 106 cells suspended in D-PBS (Invitrogen, Karlsruhe, Germany) by addition of an equal volume of 2-fold lysis buffer (62.5 mM Tris-HCl, pH 6.8, 10% glycerol, 4% SDS, 20 mM DTT, 500 mM urea, 5 mM AEBSF, 0.04% bromophenol blue) followed by ultrasound treatment (15 s, 14 W, 20 kHz, tip diameter 2 mm). For assessment of in vivo activity by immunoband depletion, cells were cultured with 100 microM VM26 (teniposide, Bristol-Myers Squibb, Munich, Germany) for 30 min prior to harvesting. Cell lysate (5 x 104 cells/lane) was subjected to SDS PAGE and transferred to PVDF membranes (Immobilon P, Millipore, Bedford, Maryland, USA). Blots were probed with the following antibodies: (i) mouse monoclonal antibodies against GFP (clone JL8, Clontech, Heidelberg, Germany), which cross react with YFP and subsequently are referred to as 'YFP antibodies'; (ii) rabbit peptide antibodies raised against a peptide of amino acid residues 1514-1531 of human topoisomerase IIalpha (CIC, Genosys Cambridge, England); (iii) rabbit polyclonal antibodies raised against a peptide of amino acid residues 1586-1621 of human topoisomerase IIbeta (designated 670) (49); (iv) various other antibodies against C-terminal epitopes of human topoisomerase IIbeta serving as a control for results obtained with 670. These include rabbit polyclonal antibodies against amino acid residues 1341-1621 (designated H-286, Santa Cruz, Heidelberg, Germany) and 1611-1621 (designated 779) (49), and mouse monoclonal antibodies against amino acid residues 1583-1601 (clone 3H10) (50).
###end p 13
###begin title 14
Immunoprecipitation and kDNA decatenation
###end title 14
###begin p 15
###xml 287 288 283 284 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">8</sup>
###xml 317 318 313 314 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">7</sup>
###xml 459 460 441 442 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 463 464 445 446 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</sub>
###xml 476 477 458 459 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 479 480 461 462 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</sub>
###xml 564 566 545 547 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;1</sup>
###xml 777 778 746 747 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 781 782 750 751 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</sub>
###xml 794 795 763 764 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 797 798 766 767 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</sub>
###xml 874 876 842 844 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;1</sup>
###xml 1222 1224 1189 1191 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;1</sup>
###xml 1311 1312 1278 1279 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
###xml 1356 1357 1323 1324 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
###xml 1499 1500 1466 1467 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 1546 1548 1512 1514 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;1</sup>
###xml 1629 1650 1589 1610 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Crithidia fasciculata</italic>
###xml 1877 1879 1833 1835 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;1</sup>
###xml 76 81 <span type="species:ncbi:9940">sheep</span>
###xml 87 92 <span type="species:ncbi:10090">mouse</span>
###xml 155 160 <span type="species:ncbi:10090">mouse</span>
###xml 1629 1650 <span type="species:ncbi:5656">Crithidia fasciculata</span>
Magnetic beads (Dynabeads M-280, Dynal/Invitrogen, Oslo, Norway) coupled to sheep anti-mouse IgG were loaded with YFP antibodies (Anti-GFP, mixture of two mouse monoclonal antibodies, Roche, Basel, Switzerland) according to the manufacturer's instructions (60 microg of antibodies per 108 beads). Loaded beads (4 x 107) were incubated (2 h at 4degreesC) with nuclear extract (200 microg total protein) in a final volume of 400 microl binding buffer (5.5 mM Na2HPO4, 1.2 mM NaH2PO4, pH 7.4, 265 mM NaCl, 5% FCS, 13.75% glycerol, 2.25 mM EDTA, 0.35 mM DTT, 10 mug ml-1 aprotinin, 1 mM AEBSF). Subsequently, beads were washed once with three volumes of binding buffer (20 min, 4degreesC), followed by four washes (10 min, 4degreesC) with three volumes of washing buffer (5.5 mM Na2HPO4, 1.2 mM NaH2PO4, pH 7.4, 890 mM NaCl, 13.75% Glycerol, 2.25 mM EDTA, 0.35 mM DTT, 10 mug ml-1 aprotinin, 1 mM AEBSF). These washing steps were found crucial for disrupting non-covalent interactions of YFP-fused topoisomerase II with endogenous topoisomerase species. Immunoprecipitates were finally eluted from the beads by boiling for 10 min in sample buffer (31.25 mM Tris-HCl, pH 6.8, 5% glycerol, 3% SDS, 2 mM DTT, 2 mM EDTA, 10 mug ml-1 aprotinin, 1 mM AEBSF). Eluates were subjected to SDS PAGE and silver staining (4 x 106 beads per lane) or western blotting (2 x 106 beads per lane). Alternatively, immunoprecipitates were washed twice with decatenation buffer (50 mM Tris-HCl, pH 7.6, 100 mM KCl, 10 mM MgCl2, 1 mM ATP, 0.5 mM DTT, 0.5 mM EDTA, 30 mug ml-1 BSA) and incubated (2 h, 37degreesC) with 300 ng catenated kinetoplast DNA from Crithidia fasciculata (kDNA, TopoGen Inc., Columbus, USA), with or without 1 mM ICRF-187 (Zinecard, Pharmacia & Upjohn, Kalamazoo, MI, USA), in a final volume of 27 microl decatenation buffer. The reaction was stopped by adding 1% SDS and 0.1 mg ml-1 proteinase K, and DNA reaction products were analyzed by agarose gel electrophoresis.
###end p 15
###begin title 16
RESULTS
###end title 16
###begin title 17
Construction of topoisomerase IIalpha/beta chimeras
###end title 17
###begin p 18
###xml 258 260 244 246 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B39">39</xref>
###xml 261 263 247 249 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B41">41</xref>
###xml 475 477 454 456 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B16">16</xref>
###xml 478 480 457 459 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B51">51</xref>
###xml 576 581 555 560 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B52 B53 B54">52&#8211;54</xref>
###xml 689 697 664 672 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 699 701 674 676 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B53">53</xref>
###xml 781 783 756 758 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B55">55</xref>
###xml 846 848 821 823 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B56">56</xref>
###xml 1570 1572 1519 1521 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B57">57</xref>
###xml 1748 1750 1697 1699 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B39">39</xref>
###xml 1751 1753 1700 1702 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B41">41</xref>
###xml 2381 2389 2285 2293 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F1">Figure 1</xref>
###xml 602 607 <span type="species:ncbi:9606">human</span>
###xml 930 935 <span type="species:ncbi:9606">human</span>
###xml 1332 1338 <span type="species:ncbi:10090">murine</span>
###xml 1424 1429 <span type="species:ncbi:9606">human</span>
###xml 1563 1568 <span type="species:ncbi:4932">yeast</span>
###xml 1642 1647 <span type="species:ncbi:9606">human</span>
###xml 1883 1888 <span type="species:ncbi:9606">human</span>
Topoisomerase IIalpha and IIbeta are composed of three functional domains, which are bordered by protease-sensitive sites. Limited proteolysis experiments revealed that the C-terminal domains begin at residues 1263 (IIalpha) and 1296 (IIbeta), respectively (39,41). However, sequence alignment shows that the region of high diversity between the two isoforms extends beyond this domain border and reaches up to amino acid positions 1171-1179 (IIalpha) or 1185-1191 (IIbeta) (16,51). Interestingly, type II enzymes from chlorella viruses lack this divergent C-terminal region (52-54), and truncation of human topoisomerase IIalpha at amino acid 1175 produced a catalytically active variant in vitro (53). An extended truncation at position 1121, however, destroyed enzyme activity (55) probably due to deletion of the primary dimerization region (56). In summary, these findings suggested to us residues 1173-1531 and 1186-1621 of human topoisomerase IIalpha and IIbeta, respectively, as candidate regions for the isoform-specific regulation. These regions encompass a maximum of heterogeneity (bearing only approximately32% identical amino acid residues) and can be exchanged between the two isoforms without interfering with the basic enzymatic functions. In fact, it has been reported that exchanging of the C-terminal regions of murine topoisomerase II isoforms at positions corresponding to amino acids 1173 and 1186 of human topoisomerase IIalpha and IIbeta, respectively, gives rise to chimeric enzymes that are fully active upon heterologous expression in yeast (57). Therefore, we chose to exchange the same C-terminal regions of the human enzymes. Because these regions extend beyond the C-terminal domains defined by limited proteolysis (39,41), they are herein referred to as C-terminal regions (CTRs). We also selected short divergent stretches at the N-terminal ends of human topoisomerase IIalpha and IIbeta (first 27 or 43 amino acids, respectively) to be exchanged between isoforms. These regions are only approximately14% identical, whereas the rest of the N-terminal domains and the core domains (amino acids 28-1172 and 44-1185 of IIalpha and IIbeta, respectively) are very similar with approximately81% identical amino acid residues. A synopsis of sequence homologies and sites chosen for exchanging regions between topoisomerase IIalpha and IIbeta is shown in Figure 1A.
###end p 18
###begin title 19
Constitutive expression of active topoisomerase IIalpha/beta-chimeras in HEK 293 cells
###end title 19
###begin p 20
###xml 72 80 72 80 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F1">Figure 1</xref>
###xml 807 815 793 801 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F2">Figure 2</xref>
###xml 1269 1277 1248 1256 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F2">Figure 2</xref>
###xml 1598 1606 1570 1578 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F2">Figure 2</xref>
###xml 1878 1886 1850 1858 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F1">Figure 1</xref>
###xml 2063 2071 2028 2036 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F2">Figure 2</xref>
###xml 2292 2300 2257 2265 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F2">Figure 2</xref>
###xml 2705 2713 2667 2675 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F2">Figure 2</xref>
###xml 3208 3216 3163 3171 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F2">Figure 2</xref>
###xml 3567 3569 3503 3505 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B38">38</xref>
###xml 2423 2428 <span type="species:ncbi:9606">human</span>
When transfected into HEK 293 cells, each of the constructs depicted in Figure 1B gave rise to viable cell lines supporting stable expression of the YFP-fused proteins. Cell clones with intermediate expression levels were selected and expanded for further analysis. All clones exhibited growth rates and gross morphologies similar to cells not transfected or expressing YFP alone. To assess the integrity of the fusion proteins and to compare their relative expression levels, we subjected the cells to western blotting and probed the blots with YFP antibodies. YFP-fused full-length, non-chimeric topoisomerase IIalpha and IIbeta and the various topoisomerase IIalpha/beta chimeras were detected as single protein bands of expected size. There were no smaller bands detected in addition by YFP antibodies (Figure 2A, top, odd numbered lanes). Thus, we could exclude rearrangements of the transgenes and safely assume that yellow fluorescence of the cells was entirely due to the desired YFP-fused protein. All constructs supported similar expression levels allowing a comparison of data between these cells. To compare YFP-fused and endogenous enzymes, blots were probed with isoform-specific antibodies against C-terminal epitopes of topoisomerase IIalpha or IIbeta (Figure 2A, middle and bottom, respectively). The YFP-fused proteins could clearly be discriminated from the corresponding endogenous enzymes as additional bands of slower migration. From comparison of lanes it became evident that endogenous levels of topoisomerase IIalpha and IIbeta were similar in all transfected cell clones (Figure 2A, middle and bottom, odd numbered lanes) and similar to those in untransfected cells (not shown), indicating that none of the YFP-fused enzymes interfered with endogenous topoisomerase II expression. It should also be noted that the desired exchanges of CTRs outlined in Figure 1B were confirmed by the presence of unique C-terminal epitopes of topoisomerase IIalpha and IIbeta in the products of the various constructs shown in middle and bottom panel of Figure 2A. To compare expression levels of endogenous and YFP-fused proteins within each clone, we intended to compare signal intensity within the lanes of western blots stained with isoform-specific topoisomerase II antibodies (Figure 2A, middle and bottom, odd numbered lanes). However, upon testing several antibodies directed at various unique epitopes of human topoisomerase IIbeta, we found that all antibodies tested did not exhibit the same preference for the endogenous form and heterologously expressed YFP-fused variants of the enzyme. On the contrary, the antibodies preferentially recognized one or the other form of the enzyme (Figure 2B). Thus, conclusions about expression levels drawn from such analyses are in our eyes unreliable. However, it should be noted that all cell clones expressing YFP-fused enzyme constructs exhibited growth rates and morphologies indistinguishable from untransfected cells, suggesting that the enzymes were at least expressed at physiologically tolerable levels. Similar analyses were carried out on cell clones expressing YFP fusion proteins of the CTRs of topoisomerase IIalpha and IIbeta alone (Figure 2C). These constructs also gave rise to single protein bands. However, the apparent molecular weight (approximately100 kDa in both cases) was larger than expected from the amino acid sequence (70 kDa for alpha CTR-YFP and 80 kDa for beta CTR-YFP). This could be due to phosphorylation, since these regions harbor the majority of phosphorylation sites (38).
###end p 20
###begin p 21
###xml 251 252 251 252 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B4">4</xref>
###xml 446 454 446 454 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F2">Figure 2</xref>
###xml 635 643 628 636 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F2">Figure 2</xref>
###xml 776 784 765 773 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F2">Figure 2</xref>
###xml 807 815 793 801 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F2">Figure 2</xref>
###xml 901 909 887 895 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F2">Figure 2</xref>
###xml 1454 1463 1426 1435 <label xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 2.</label>
###xml 1620 1628 1592 1600 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F1">Figure 1</xref>
###xml 1667 1668 1639 1640 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 2160 2161 2114 2115 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
###xml 2611 2612 2556 2557 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</bold>
###xml 1463 2958 1435 2874 <p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" textid="22">Immunoblot analysis of YFP-fused topoisomerase II constructs expressed in HEK 293 cells. Positions of marker proteins are indicated on the right margin. See <xref ref-type="fig" rid="F1">Figure 1</xref>B for nomenclature of the constructs. (<bold>A</bold>) Topoisomerase II immunoband depletion assay. Lysates of whole cells expressing full-length human topoisomerase II&#945; (lanes 1 and 2), or II&#946; (lanes 3 and 4), or enzyme chimeras (lanes 5&#8211;12) were subjected to SDS PAGE (6% gels) and western blotting. Blots were stained with YFP antibodies (top), or antibodies against human topoisomerase II&#945; (middle), or II&#946; (mixture of antibodies 779 and 3H10, bottom). Cells in even lanes were first cultured with 100&#8201;&#181;M VM26 for 30&#8201;min. (<bold>B</bold>) Specificity of topoisomerase II&#946; antibodies in immunostaining of western blots. Whole cell lysates of cells expressing full-length human topoisomerase II&#946;, were subjected to SDS PAGE (6% gels) and western blotting. Blot membranes were probed with YFP antibodies (lane 1, JL-8) or antibodies against topoisomerase II&#946;, as follows. Lane 2 (670), lane 3 (779), lane 4 (3H10), lane 5 (a mixture of antibodies 779 and 3H10) and lane 6 (H286). (<bold>C</bold>) Lysates of whole cells expressing human topoisomerase II&#945; &#916;1&#8211;1172 (&#945; CTR, odd numbered lanes) or II&#946; &#916;1&#8211;1185 (&#946; CTR, even numbered lanes) were subjected to SDS PAGE (10% gels) and western blotting. Blots were probed with YFP-antibodies (left), or antibodies against human topoisomerase II&#945; (middle), or II&#946; (right).</p>
###xml 1463 2958 1435 2874 <caption xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><p textid="22">Immunoblot analysis of YFP-fused topoisomerase II constructs expressed in HEK 293 cells. Positions of marker proteins are indicated on the right margin. See <xref ref-type="fig" rid="F1">Figure 1</xref>B for nomenclature of the constructs. (<bold>A</bold>) Topoisomerase II immunoband depletion assay. Lysates of whole cells expressing full-length human topoisomerase II&#945; (lanes 1 and 2), or II&#946; (lanes 3 and 4), or enzyme chimeras (lanes 5&#8211;12) were subjected to SDS PAGE (6% gels) and western blotting. Blots were stained with YFP antibodies (top), or antibodies against human topoisomerase II&#945; (middle), or II&#946; (mixture of antibodies 779 and 3H10, bottom). Cells in even lanes were first cultured with 100&#8201;&#181;M VM26 for 30&#8201;min. (<bold>B</bold>) Specificity of topoisomerase II&#946; antibodies in immunostaining of western blots. Whole cell lysates of cells expressing full-length human topoisomerase II&#946;, were subjected to SDS PAGE (6% gels) and western blotting. Blot membranes were probed with YFP antibodies (lane 1, JL-8) or antibodies against topoisomerase II&#946;, as follows. Lane 2 (670), lane 3 (779), lane 4 (3H10), lane 5 (a mixture of antibodies 779 and 3H10) and lane 6 (H286). (<bold>C</bold>) Lysates of whole cells expressing human topoisomerase II&#945; &#916;1&#8211;1172 (&#945; CTR, odd numbered lanes) or II&#946; &#916;1&#8211;1185 (&#946; CTR, even numbered lanes) were subjected to SDS PAGE (10% gels) and western blotting. Blots were probed with YFP-antibodies (left), or antibodies against human topoisomerase II&#945; (middle), or II&#946; (right).</p></caption>
###xml 2958 2958 2874 2874 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xlink:href="gkm102f2"/>
###xml 1454 2958 1426 2874 <fig xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="F2" position="float"><label>Figure 2.</label><caption><p textid="22">Immunoblot analysis of YFP-fused topoisomerase II constructs expressed in HEK 293 cells. Positions of marker proteins are indicated on the right margin. See <xref ref-type="fig" rid="F1">Figure 1</xref>B for nomenclature of the constructs. (<bold>A</bold>) Topoisomerase II immunoband depletion assay. Lysates of whole cells expressing full-length human topoisomerase II&#945; (lanes 1 and 2), or II&#946; (lanes 3 and 4), or enzyme chimeras (lanes 5&#8211;12) were subjected to SDS PAGE (6% gels) and western blotting. Blots were stained with YFP antibodies (top), or antibodies against human topoisomerase II&#945; (middle), or II&#946; (mixture of antibodies 779 and 3H10, bottom). Cells in even lanes were first cultured with 100&#8201;&#181;M VM26 for 30&#8201;min. (<bold>B</bold>) Specificity of topoisomerase II&#946; antibodies in immunostaining of western blots. Whole cell lysates of cells expressing full-length human topoisomerase II&#946;, were subjected to SDS PAGE (6% gels) and western blotting. Blot membranes were probed with YFP antibodies (lane 1, JL-8) or antibodies against topoisomerase II&#946;, as follows. Lane 2 (670), lane 3 (779), lane 4 (3H10), lane 5 (a mixture of antibodies 779 and 3H10) and lane 6 (H286). (<bold>C</bold>) Lysates of whole cells expressing human topoisomerase II&#945; &#916;1&#8211;1172 (&#945; CTR, odd numbered lanes) or II&#946; &#916;1&#8211;1185 (&#946; CTR, even numbered lanes) were subjected to SDS PAGE (10% gels) and western blotting. Blots were probed with YFP-antibodies (left), or antibodies against human topoisomerase II&#945; (middle), or II&#946; (right).</p></caption><graphic xlink:href="gkm102f2"/></fig>
###xml 1761 1766 <span type="species:ncbi:9606">human</span>
###xml 1992 1997 <span type="species:ncbi:9606">human</span>
###xml 2297 2302 <span type="species:ncbi:9606">human</span>
###xml 2648 2653 <span type="species:ncbi:9606">human</span>
###xml 2902 2907 <span type="species:ncbi:9606">human</span>
To determine whether the exogenous enzymes were as active in the cells as the endogenous enzymes, we employed immunoband depletion. The assay is based on the stabilization of covalent complexes of topoisomerase II and genomic DNA by specific poisons (4). As a consequence, signals specific for active topoisomerase II molecules are depleted from immunoblots due to retention of topoisomerase II*DNA complexes in the gel slots. As demonstrated in Figure 2A, treatment with the topoisomerase II poison VM26 depleted YFP-fused non-chimeric full-length enzymes and topoisomerase IIalpha/beta chimeras from immunoblots to a similar extent (Figure 2A, top, compare lanes 1-4 with lanes 5-12). The extent of depletion was also comparable to that of endogenous topoisomerase IIalpha (Figure 2A, middle) and IIbeta (Figure 2A, bottom). It should be noted that in this analysis antibody-derived biases (compare Figure 2B) did not play a role since they apply in the same manner to the bands to be compared in quantitative terms. These results confirm that all the topoisomerase IIalpha/beta chimeras were active in the cells. Moreover, it could be deduced that activity levels were comparable to those of non-chimeric enzymes (exogenous or endogenous) because bands were depleted to similar extent. Corresponding analyses of cells expressing the YFP-tagged alpha CTR or beta CTR confirmed that these proteins were catalytically inactive, as predicted (not shown). Figure 2.Immunoblot analysis of YFP-fused topoisomerase II constructs expressed in HEK 293 cells. Positions of marker proteins are indicated on the right margin. See Figure 1B for nomenclature of the constructs. (A) Topoisomerase II immunoband depletion assay. Lysates of whole cells expressing full-length human topoisomerase IIalpha (lanes 1 and 2), or IIbeta (lanes 3 and 4), or enzyme chimeras (lanes 5-12) were subjected to SDS PAGE (6% gels) and western blotting. Blots were stained with YFP antibodies (top), or antibodies against human topoisomerase IIalpha (middle), or IIbeta (mixture of antibodies 779 and 3H10, bottom). Cells in even lanes were first cultured with 100 microM VM26 for 30 min. (B) Specificity of topoisomerase IIbeta antibodies in immunostaining of western blots. Whole cell lysates of cells expressing full-length human topoisomerase IIbeta, were subjected to SDS PAGE (6% gels) and western blotting. Blot membranes were probed with YFP antibodies (lane 1, JL-8) or antibodies against topoisomerase IIbeta, as follows. Lane 2 (670), lane 3 (779), lane 4 (3H10), lane 5 (a mixture of antibodies 779 and 3H10) and lane 6 (H286). (C) Lysates of whole cells expressing human topoisomerase IIalpha Delta1-1172 (alpha CTR, odd numbered lanes) or IIbeta Delta1-1185 (beta CTR, even numbered lanes) were subjected to SDS PAGE (10% gels) and western blotting. Blots were probed with YFP-antibodies (left), or antibodies against human topoisomerase IIalpha (middle), or IIbeta (right).
###end p 21
###begin p 22
###xml 157 165 157 165 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F1">Figure 1</xref>
###xml 204 205 204 205 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 697 698 679 680 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
###xml 1148 1149 1121 1122 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</bold>
###xml 298 303 <span type="species:ncbi:9606">human</span>
###xml 529 534 <span type="species:ncbi:9606">human</span>
###xml 834 839 <span type="species:ncbi:9606">human</span>
###xml 1185 1190 <span type="species:ncbi:9606">human</span>
###xml 1439 1444 <span type="species:ncbi:9606">human</span>
Immunoblot analysis of YFP-fused topoisomerase II constructs expressed in HEK 293 cells. Positions of marker proteins are indicated on the right margin. See Figure 1B for nomenclature of the constructs. (A) Topoisomerase II immunoband depletion assay. Lysates of whole cells expressing full-length human topoisomerase IIalpha (lanes 1 and 2), or IIbeta (lanes 3 and 4), or enzyme chimeras (lanes 5-12) were subjected to SDS PAGE (6% gels) and western blotting. Blots were stained with YFP antibodies (top), or antibodies against human topoisomerase IIalpha (middle), or IIbeta (mixture of antibodies 779 and 3H10, bottom). Cells in even lanes were first cultured with 100 microM VM26 for 30 min. (B) Specificity of topoisomerase IIbeta antibodies in immunostaining of western blots. Whole cell lysates of cells expressing full-length human topoisomerase IIbeta, were subjected to SDS PAGE (6% gels) and western blotting. Blot membranes were probed with YFP antibodies (lane 1, JL-8) or antibodies against topoisomerase IIbeta, as follows. Lane 2 (670), lane 3 (779), lane 4 (3H10), lane 5 (a mixture of antibodies 779 and 3H10) and lane 6 (H286). (C) Lysates of whole cells expressing human topoisomerase IIalpha Delta1-1172 (alpha CTR, odd numbered lanes) or IIbeta Delta1-1185 (beta CTR, even numbered lanes) were subjected to SDS PAGE (10% gels) and western blotting. Blots were probed with YFP-antibodies (left), or antibodies against human topoisomerase IIalpha (middle), or IIbeta (right).
###end p 22
###begin title 23
Impact of non-conserved regions on localization of topoisomerase II in living cells
###end title 23
###begin p 24
###xml 50 52 50 52 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B43">43</xref>
###xml 65 72 65 72 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 138 140 131 133 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B44">44</xref>
###xml 303 311 296 304 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F3">Figure 3</xref>
###xml 690 698 669 677 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F3">Figure 3</xref>
###xml 1289 1297 1240 1248 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F3">Figure 3</xref>
###xml 1334 1342 1285 1293 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F3">Figure 3</xref>
###xml 1504 1512 1451 1459 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F3">Figure 3</xref>
###xml 1586 1594 1533 1541 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F3">Figure 3</xref>
###xml 1741 1749 1681 1689 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F3">Figure 3</xref>
###xml 1884 1892 1817 1825 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F3">Figure 3</xref>
###xml 2010 2018 1943 1951 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F3">Figure 3</xref>
###xml 2209 2217 2139 2147 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F3">Figure 3</xref>
###xml 2620 2629 2543 2552 <label xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 3.</label>
###xml 2629 2636 2552 2559 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">In vivo</italic>
###xml 2725 2726 2648 2649 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 2983 2984 2899 2900 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
###xml 3150 3158 3066 3074 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F1">Figure 1</xref>
###xml 2629 3454 2552 3370 <p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" textid="25"><italic>In vivo</italic> localization of topoisomerase II constructs in interphase nuclei and during metaphase. (<bold>A</bold>) Representative examples of HEK 293 cells stably co-expressing topoisomerase II&#945; fused to CFP (pseudo-colored in red) and topoisomerase II&#946; fused to YFP (green) visualized by confocal imaging at interphase (left column) and mitosis (right column). (<bold>B</bold>) Each row of images shows representative images of living HEK 293 cells stably expressing the YFP-fused topoisomerase II construct indicated on the left margin (see <xref ref-type="fig" rid="F1">Figure 1</xref>B for nomenclature) or YFP alone (row 9). Each pair of images visualizes the same cell by transmitted light (left) and confocal imaging of YFP-fluorescence in mid plane (right). Left and right columns of image pairs show representative examples of cells at interphase and metaphase, respectively.</p>
###xml 2629 3454 2552 3370 <caption xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><p textid="25"><italic>In vivo</italic> localization of topoisomerase II constructs in interphase nuclei and during metaphase. (<bold>A</bold>) Representative examples of HEK 293 cells stably co-expressing topoisomerase II&#945; fused to CFP (pseudo-colored in red) and topoisomerase II&#946; fused to YFP (green) visualized by confocal imaging at interphase (left column) and mitosis (right column). (<bold>B</bold>) Each row of images shows representative images of living HEK 293 cells stably expressing the YFP-fused topoisomerase II construct indicated on the left margin (see <xref ref-type="fig" rid="F1">Figure 1</xref>B for nomenclature) or YFP alone (row 9). Each pair of images visualizes the same cell by transmitted light (left) and confocal imaging of YFP-fluorescence in mid plane (right). Left and right columns of image pairs show representative examples of cells at interphase and metaphase, respectively.</p></caption>
###xml 3454 3454 3370 3370 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xlink:href="gkm102f3"/>
###xml 2620 3454 2543 3370 <fig xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="F3" position="float"><label>Figure 3.</label><caption><p textid="25"><italic>In vivo</italic> localization of topoisomerase II constructs in interphase nuclei and during metaphase. (<bold>A</bold>) Representative examples of HEK 293 cells stably co-expressing topoisomerase II&#945; fused to CFP (pseudo-colored in red) and topoisomerase II&#946; fused to YFP (green) visualized by confocal imaging at interphase (left column) and mitosis (right column). (<bold>B</bold>) Each row of images shows representative images of living HEK 293 cells stably expressing the YFP-fused topoisomerase II construct indicated on the left margin (see <xref ref-type="fig" rid="F1">Figure 1</xref>B for nomenclature) or YFP alone (row 9). Each pair of images visualizes the same cell by transmitted light (left) and confocal imaging of YFP-fluorescence in mid plane (right). Left and right columns of image pairs show representative examples of cells at interphase and metaphase, respectively.</p></caption><graphic xlink:href="gkm102f3"/></fig>
We have previously shown by immunohistochemistry (43) as well as in vivo localization of biofluorescent topoisomerase IIalpha and IIbeta (44) that the most obvious difference between the isoforms is their association with metaphase chromosomes. This observation is demonstrated in the first two rows of Figure 3B. YFP-fused topoisomerase IIalpha (row 1) and IIbeta (row 2) exhibit a similar distribution in the interphase nucleus (left). However, at metaphase (right) the alpha isoenzyme accumulates on the condensed chromosomes, whereas the beta isoenzyme diffuses mostly into the cytosol and shows only a marginal association with chromosomes. The phenomenon is even more clearly seen in Figure 3A showing cells co-expressing topoisomerase IIalpha and IIbeta fused to CFP and YFP, respectively. At interphase (left panel), the two isoenzymes colocalize, whereas at mitosis (right panel) topoisomerase IIalpha (shown in red) is chromosome bound, and topoisomerase IIbeta (shown in green) predominantly resides in the cytosol. Thus, binding to metaphase chromosomes can be used as experimental readout of isoform-specific functioning of topoisomerase IIalpha and IIbeta in proliferating mammalian cells, and we have used it to characterize the various topoisomerase IIalpha/beta chimeras (Figure 3B, rows 3-6) and the two CTRs alone (Figure 3B, rows 7 and 8). It becomes readily apparent, that the ability to bind to metaphase chromosomes is fully retained in all enzyme varieties bearing the alpha CTR (Figure 3B, rows 1, 3 and 6) and to some extent also in this enzyme portion alone (Figure 3B, row 7). Moreover, enrichment in mitotic chromosomes is lost from topoisomerase IIalpha, when its CTR is replaced with that of the beta isoform (Figure 3B, row 5). Conversely, this property is fully gained by topoisomerase IIbeta, when its CTR is replaced with that of the alpha isoform (Figure 3B, row 6). Similar effects are not apparent upon exchanging the non-conserved N-terminal stretches of the isoenzymes (Figure 3B, compare rows 3 and 4). It should be noted that the beta CTR alone had a diffuse distribution in the cell at metaphase, but it was not entirely excluded from chromosomes, as was YFP alone (Figure 3B, row 9). In summary, these observations suggest that (i) the non-conserved CTR of topoisomerase IIalpha promotes binding of the enzyme to metaphase chromosomes, (ii) the corresponding CTR of topoisomerase IIbeta is much less capable of performing this function, and (iii) the non-conserved N-terminal stretches of the two isozymes do not play a role in targeting the enzymes to metaphase chromosomes. Figure 3.In vivo localization of topoisomerase II constructs in interphase nuclei and during metaphase. (A) Representative examples of HEK 293 cells stably co-expressing topoisomerase IIalpha fused to CFP (pseudo-colored in red) and topoisomerase IIbeta fused to YFP (green) visualized by confocal imaging at interphase (left column) and mitosis (right column). (B) Each row of images shows representative images of living HEK 293 cells stably expressing the YFP-fused topoisomerase II construct indicated on the left margin (see Figure 1B for nomenclature) or YFP alone (row 9). Each pair of images visualizes the same cell by transmitted light (left) and confocal imaging of YFP-fluorescence in mid plane (right). Left and right columns of image pairs show representative examples of cells at interphase and metaphase, respectively.
###end p 24
###begin p 25
###xml 0 7 0 7 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">In vivo</italic>
###xml 96 97 96 97 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 354 355 347 348 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
###xml 521 529 514 522 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F1">Figure 1</xref>
In vivo localization of topoisomerase II constructs in interphase nuclei and during metaphase. (A) Representative examples of HEK 293 cells stably co-expressing topoisomerase IIalpha fused to CFP (pseudo-colored in red) and topoisomerase IIbeta fused to YFP (green) visualized by confocal imaging at interphase (left column) and mitosis (right column). (B) Each row of images shows representative images of living HEK 293 cells stably expressing the YFP-fused topoisomerase II construct indicated on the left margin (see Figure 1B for nomenclature) or YFP alone (row 9). Each pair of images visualizes the same cell by transmitted light (left) and confocal imaging of YFP-fluorescence in mid plane (right). Left and right columns of image pairs show representative examples of cells at interphase and metaphase, respectively.
###end p 25
###begin title 26
The dimerization state of topoisomerase IIalpha/beta chimeras
###end title 26
###begin p 27
###xml 90 98 90 98 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F3">Figure 3</xref>
###xml 555 557 548 550 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B44">44</xref>
###xml 803 805 789 791 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B44">44</xref>
###xml 1256 1264 1242 1250 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F4">Figure 4</xref>
###xml 1486 1494 1458 1466 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F4">Figure 4</xref>
###xml 1812 1814 1784 1786 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B58">58</xref>
###xml 1967 1969 1939 1941 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B44">44</xref>
###xml 2035 2037 2007 2009 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B59">59</xref>
###xml 2099 2101 2071 2073 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B59">59</xref>
###xml 2340 2348 2312 2320 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F4">Figure 4</xref>
###xml 2819 2821 2791 2793 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B60">60</xref>
###xml 2968 2975 2933 2940 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 3008 3016 2973 2981 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F3">Figure 3</xref>
###xml 3160 3169 3121 3130 <label xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 4.</label>
###xml 3275 3283 3236 3244 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 3286 3287 3247 3248 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 3340 3348 3301 3309 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F1">Figure 1</xref>
###xml 3793 3794 3747 3748 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
###xml 3169 4201 3130 4155 <p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" textid="28">Immunoprecipitation of YFP-fused topoisomerase II constructs followed by determination of enzyme activity <italic>in vitro</italic>. (<bold>A</bold>) Topoisomerase constructs indicated at the top (see <xref ref-type="fig" rid="F1">Figure 1</xref>B for nomenclature) were stably expressed in HEK 293 cells and subjected to YFP-directed immunoprecipitation. Precipitates were analyzed by SDS PAGE (6% gels) and protein silver staining (top), or subjected to western blotting and probed with YFP antibodies (middle top), or antibodies against topoisomerase II&#945; (middle bottom), or II&#946; (bottom). Migration distances of molecular weight marker proteins are indicated on the right margin. (<bold>B</bold>) Alternatively, precipitates were reacted with 300&#8201;ng kDNA in the absence (odd numbered lanes) or presence (even numbered lanes) of 1&#8201;mM ICRF-187. DNA-reaction products were separated by agarose gel electrophoresis and visualized with ethidium bromide. Positions of catenated DNA network and free DNA circles are indicated on the right margin. The first lane on the left (c) shows the kDNA substrate alone.</p>
###xml 3169 4201 3130 4155 <caption xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><p textid="28">Immunoprecipitation of YFP-fused topoisomerase II constructs followed by determination of enzyme activity <italic>in vitro</italic>. (<bold>A</bold>) Topoisomerase constructs indicated at the top (see <xref ref-type="fig" rid="F1">Figure 1</xref>B for nomenclature) were stably expressed in HEK 293 cells and subjected to YFP-directed immunoprecipitation. Precipitates were analyzed by SDS PAGE (6% gels) and protein silver staining (top), or subjected to western blotting and probed with YFP antibodies (middle top), or antibodies against topoisomerase II&#945; (middle bottom), or II&#946; (bottom). Migration distances of molecular weight marker proteins are indicated on the right margin. (<bold>B</bold>) Alternatively, precipitates were reacted with 300&#8201;ng kDNA in the absence (odd numbered lanes) or presence (even numbered lanes) of 1&#8201;mM ICRF-187. DNA-reaction products were separated by agarose gel electrophoresis and visualized with ethidium bromide. Positions of catenated DNA network and free DNA circles are indicated on the right margin. The first lane on the left (c) shows the kDNA substrate alone.</p></caption>
###xml 4201 4201 4155 4155 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xlink:href="gkm102f4"/>
###xml 3160 4201 3121 4155 <fig xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="F4" position="float"><label>Figure 4.</label><caption><p textid="28">Immunoprecipitation of YFP-fused topoisomerase II constructs followed by determination of enzyme activity <italic>in vitro</italic>. (<bold>A</bold>) Topoisomerase constructs indicated at the top (see <xref ref-type="fig" rid="F1">Figure 1</xref>B for nomenclature) were stably expressed in HEK 293 cells and subjected to YFP-directed immunoprecipitation. Precipitates were analyzed by SDS PAGE (6% gels) and protein silver staining (top), or subjected to western blotting and probed with YFP antibodies (middle top), or antibodies against topoisomerase II&#945; (middle bottom), or II&#946; (bottom). Migration distances of molecular weight marker proteins are indicated on the right margin. (<bold>B</bold>) Alternatively, precipitates were reacted with 300&#8201;ng kDNA in the absence (odd numbered lanes) or presence (even numbered lanes) of 1&#8201;mM ICRF-187. DNA-reaction products were separated by agarose gel electrophoresis and visualized with ethidium bromide. Positions of catenated DNA network and free DNA circles are indicated on the right margin. The first lane on the left (c) shows the kDNA substrate alone.</p></caption><graphic xlink:href="gkm102f4"/></fig>
Given that topoisomerase II functions as a dimer, unambiguous deductions from the data in Figure 3 can only be made, when dimerization of topoisomerase IIalpha/beta chimeras with endogenous enzyme varieties can be excluded, because this would render the behavior of the YFP-linked moiety attributable to an unpredictable mixture of homo- and heterodimers. In fact, we have previously assumed dimerization between GFP-fused, wild-type topoisomerase II and corresponding endogenous enzyme molecules based on GFP-directed immunoprecipitation (IP) protocols (44). We therefore wanted to clearly define the dimerization state of the topoisomerase IIalpha/beta chimeras by YFP-directed IP followed by SDS PAGE, protein staining and immunoblotting. When we applied previously described low-salt IP conditions (44) to extracts from cell lines investigated here, the results were highly inconsistent, and non-reproducible; often both endogenous topo II isoforms were detected in the IPs by immunoblotting (data not shown). To address these problems we applied harsher buffer conditions with higher salt concentrations. Under these conditions, no prominent protein bands, other than the expected YFP-chimeras, were detected in silver-stained gels of any of the IPs (Figure 4A, top), at least not in the size range where endogenous topoisomerase IIalpha or IIbeta would migrate (i.e. 170-180 kDa). Similarly, endogenous topoisomerase IIalpha or IIbeta were undetectable in immunoblots of the IPs (Figure 4A, middle-bottom and bottom), the only protein species detected being the ones directly targeted by the precipitating YFP antibody. It is unlikely that this difference to our previous results was brought about by experimental dissociation of topoisomerase II dimers because they are known to be extremely salt-stable (58). We find it more likely that the presence of endogenous topoisomerase II isoforms in IPs of GFP-tagged topoisomerase II, as reported previously by us (44), was due to the multimerization of topoisomerase II homodimers (59), which is known to decrease with increasing ionic strength (59). To further demonstrate that topoisomerase II dimers were not disrupted during high salt IP, we tested whether the enzymes retained their catalytic activity (indicative of functional dimeric enzymes) in the final IPs. As demonstrated in Figure 4B, IPs of all the YFP-tagged proteins exhibited strong DNA decatenation activity, thus attesting to the integrity of the enzyme dimers throughout the IP procedure. Thus, the most plausible conclusion is that all the exogenous topoisomerase II species heterologously expressed in HEK 293 cells undergo homodimer formation. Because these observations were based on IPs of YFP-tagged proteins, they do not rule out the formation of endogenous topoisomerase II heterodimers (60). They do, however, allow for an unambiguous interpretation of the data obtained here with the various topoisomerase IIalpha/beta chimeras. Thus, in vivo localization of these proteins (Figure 3B) clearly indicates a decisive role of the non-conserved alpha CTR in targeting the core portion of topoisomerase II to metaphase chromosomes. Figure 4.Immunoprecipitation of YFP-fused topoisomerase II constructs followed by determination of enzyme activity in vitro. (A) Topoisomerase constructs indicated at the top (see Figure 1B for nomenclature) were stably expressed in HEK 293 cells and subjected to YFP-directed immunoprecipitation. Precipitates were analyzed by SDS PAGE (6% gels) and protein silver staining (top), or subjected to western blotting and probed with YFP antibodies (middle top), or antibodies against topoisomerase IIalpha (middle bottom), or IIbeta (bottom). Migration distances of molecular weight marker proteins are indicated on the right margin. (B) Alternatively, precipitates were reacted with 300 ng kDNA in the absence (odd numbered lanes) or presence (even numbered lanes) of 1 mM ICRF-187. DNA-reaction products were separated by agarose gel electrophoresis and visualized with ethidium bromide. Positions of catenated DNA network and free DNA circles are indicated on the right margin. The first lane on the left (c) shows the kDNA substrate alone.
###end p 27
###begin p 28
###xml 106 114 106 114 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 117 118 117 118 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 171 179 171 179 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F1">Figure 1</xref>
###xml 624 625 617 618 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
Immunoprecipitation of YFP-fused topoisomerase II constructs followed by determination of enzyme activity in vitro. (A) Topoisomerase constructs indicated at the top (see Figure 1B for nomenclature) were stably expressed in HEK 293 cells and subjected to YFP-directed immunoprecipitation. Precipitates were analyzed by SDS PAGE (6% gels) and protein silver staining (top), or subjected to western blotting and probed with YFP antibodies (middle top), or antibodies against topoisomerase IIalpha (middle bottom), or IIbeta (bottom). Migration distances of molecular weight marker proteins are indicated on the right margin. (B) Alternatively, precipitates were reacted with 300 ng kDNA in the absence (odd numbered lanes) or presence (even numbered lanes) of 1 mM ICRF-187. DNA-reaction products were separated by agarose gel electrophoresis and visualized with ethidium bromide. Positions of catenated DNA network and free DNA circles are indicated on the right margin. The first lane on the left (c) shows the kDNA substrate alone.
###end p 28
###begin title 29
The CTR of topoisomerase IIalpha is required for the efficient support of cell proliferation
###end title 29
###begin p 30
###xml 86 94 82 90 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F3">Figure 3</xref>
###xml 514 516 498 500 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B26">26</xref>
###xml 711 719 691 699 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F1">Figure 1</xref>
###xml 847 854 827 834 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T1">Table 1</xref>
###xml 1989 1997 1941 1949 <label xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Table 1.</label>
###xml 2080 2081 2018 2019 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">a</sup>
###xml 2080 2081 2018 2019 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table-fn" rid="TF1"><sup>a</sup></xref>
###xml 1997 2081 1949 2019 <p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" textid="31">HTETOP complementation with topoisomerase II&#945;, II&#946; and II&#945;/&#946;-chimeras<xref ref-type="table-fn" rid="TF1"><sup>a</sup></xref></p>
###xml 1997 2081 1949 2019 <caption xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><p textid="31">HTETOP complementation with topoisomerase II&#945;, II&#946; and II&#945;/&#946;-chimeras<xref ref-type="table-fn" rid="TF1"><sup>a</sup></xref></p></caption>
###xml 2090 2091 2028 2029 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">b</sup>
###xml 2090 2091 2028 2029 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table-fn" rid="TF2"><sup>b</sup></xref>
###xml 2081 2091 2019 2029 <th xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rowspan="1" colspan="1">Construct<xref ref-type="table-fn" rid="TF2"><sup>b</sup></xref></th>
###xml 2094 2095 2032 2033 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">c</sup>
###xml 2094 2095 2032 2033 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table-fn" rid="TF3"><sup>c</sup></xref>
###xml 2091 2099 2029 2037 <th xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rowspan="1" colspan="1">TET<xref ref-type="table-fn" rid="TF3"><sup>c</sup></xref> (%)</th>
###xml 2103 2104 2041 2042 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">c</sup>
###xml 2103 2104 2041 2042 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table-fn" rid="TF3"><sup>c</sup></xref>
###xml 2099 2108 2037 2046 <th xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rowspan="1" colspan="1">PURO<xref ref-type="table-fn" rid="TF3"><sup>c</sup></xref> (%)</th>
###xml 2110 2111 2048 2049 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">d</sup>
###xml 2110 2111 2048 2049 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table-fn" rid="TF4"><sup>d</sup></xref>
###xml 2108 2111 2046 2049 <th xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rowspan="1" colspan="1">CI<xref ref-type="table-fn" rid="TF4"><sup>d</sup></xref></th>
###xml 2081 2111 2019 2049 <tr xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><th rowspan="1" colspan="1">Construct<xref ref-type="table-fn" rid="TF2"><sup>b</sup></xref></th><th rowspan="1" colspan="1">TET<xref ref-type="table-fn" rid="TF3"><sup>c</sup></xref> (%)</th><th rowspan="1" colspan="1">PURO<xref ref-type="table-fn" rid="TF3"><sup>c</sup></xref> (%)</th><th rowspan="1" colspan="1">CI<xref ref-type="table-fn" rid="TF4"><sup>d</sup></xref></th></tr>
###xml 2081 2111 2019 2049 <thead xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" align="left"><tr><th rowspan="1" colspan="1">Construct<xref ref-type="table-fn" rid="TF2"><sup>b</sup></xref></th><th rowspan="1" colspan="1">TET<xref ref-type="table-fn" rid="TF3"><sup>c</sup></xref> (%)</th><th rowspan="1" colspan="1">PURO<xref ref-type="table-fn" rid="TF3"><sup>c</sup></xref> (%)</th><th rowspan="1" colspan="1">CI<xref ref-type="table-fn" rid="TF4"><sup>d</sup></xref></th></tr></thead>
###xml 2111 2123 2049 2057 <td xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rowspan="1" colspan="1">Topo II&#945;</td>
###xml 2123 2126 2057 2060 <td xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rowspan="1" colspan="1">100</td>
###xml 2126 2129 2060 2063 <td xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rowspan="1" colspan="1">100</td>
###xml 2129 2142 2063 2074 <td xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rowspan="1" colspan="1">0.91 &#177; 0.20</td>
###xml 2111 2142 2049 2074 <tr xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><td rowspan="1" colspan="1">Topo II&#945;</td><td rowspan="1" colspan="1">100</td><td rowspan="1" colspan="1">100</td><td rowspan="1" colspan="1">0.91 &#177; 0.20</td></tr>
###xml 2142 2153 2074 2082 <td xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rowspan="1" colspan="1">Topo II&#946;</td>
###xml 2153 2165 2082 2092 <td xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rowspan="1" colspan="1">11.3 &#177; 5.6</td>
###xml 2165 2178 2092 2103 <td xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rowspan="1" colspan="1">69.8 &#177; 18.1</td>
###xml 2178 2191 2103 2114 <td xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rowspan="1" colspan="1">0.14 &#177; 0.10</td>
###xml 2142 2191 2074 2114 <tr xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><td rowspan="1" colspan="1">Topo II&#946;</td><td rowspan="1" colspan="1">11.3 &#177; 5.6</td><td rowspan="1" colspan="1">69.8 &#177; 18.1</td><td rowspan="1" colspan="1">0.14 &#177; 0.10</td></tr>
###xml 2191 2205 2114 2121 <td xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rowspan="1" colspan="1">&#946; NTS/&#945;</td>
###xml 2205 2219 2121 2133 <td xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rowspan="1" colspan="1">128.6 &#177; 18.2</td>
###xml 2219 2232 2133 2144 <td xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rowspan="1" colspan="1">73.0 &#177; 11.6</td>
###xml 2232 2245 2144 2155 <td xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rowspan="1" colspan="1">1.64 &#177; 0.61</td>
###xml 2191 2245 2114 2155 <tr xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><td rowspan="1" colspan="1">&#946; NTS/&#945;</td><td rowspan="1" colspan="1">128.6 &#177; 18.2</td><td rowspan="1" colspan="1">73.0 &#177; 11.6</td><td rowspan="1" colspan="1">1.64 &#177; 0.61</td></tr>
###xml 2245 2259 2155 2162 <td xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rowspan="1" colspan="1">&#945; NTS/&#946;</td>
###xml 2259 2270 2162 2171 <td xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rowspan="1" colspan="1">5.1 &#177; 3.3</td>
###xml 2270 2283 2171 2182 <td xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rowspan="1" colspan="1">85.6 &#177; 16.8</td>
###xml 2283 2296 2182 2193 <td xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rowspan="1" colspan="1">0.11 &#177; 0.05</td>
###xml 2245 2296 2155 2193 <tr xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><td rowspan="1" colspan="1">&#945; NTS/&#946;</td><td rowspan="1" colspan="1">5.1 &#177; 3.3</td><td rowspan="1" colspan="1">85.6 &#177; 16.8</td><td rowspan="1" colspan="1">0.11 &#177; 0.05</td></tr>
###xml 2296 2310 2193 2200 <td xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rowspan="1" colspan="1">&#945;/&#946; CTR</td>
###xml 2310 2321 2200 2209 <td xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rowspan="1" colspan="1">3.9 &#177; 4.7</td>
###xml 2321 2335 2209 2221 <td xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rowspan="1" colspan="1">120.9 &#177; 42.1</td>
###xml 2335 2348 2221 2232 <td xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rowspan="1" colspan="1">0.14 &#177; 0.11</td>
###xml 2296 2348 2193 2232 <tr xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><td rowspan="1" colspan="1">&#945;/&#946; CTR</td><td rowspan="1" colspan="1">3.9 &#177; 4.7</td><td rowspan="1" colspan="1">120.9 &#177; 42.1</td><td rowspan="1" colspan="1">0.14 &#177; 0.11</td></tr>
###xml 2348 2362 2232 2239 <td xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rowspan="1" colspan="1">&#946;/&#945; CTR</td>
###xml 2362 2375 2239 2250 <td xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rowspan="1" colspan="1">69.5 &#177; 32.2</td>
###xml 2375 2388 2250 2261 <td xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rowspan="1" colspan="1">71.1 &#177; 13.3</td>
###xml 2388 2401 2261 2272 <td xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rowspan="1" colspan="1">1.08 &#177; 0.35</td>
###xml 2348 2401 2232 2272 <tr xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><td rowspan="1" colspan="1">&#946;/&#945; CTR</td><td rowspan="1" colspan="1">69.5 &#177; 32.2</td><td rowspan="1" colspan="1">71.1 &#177; 13.3</td><td rowspan="1" colspan="1">1.08 &#177; 0.35</td></tr>
###xml 2401 2418 2272 2289 <td xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rowspan="1" colspan="1">Mock transfection</td>
###xml 2418 2419 2289 2290 <td xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rowspan="1" colspan="1">0</td>
###xml 2419 2420 2290 2291 <td xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rowspan="1" colspan="1">0</td>
###xml 2420 2421 2291 2292 <td xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rowspan="1" colspan="1">&#8211;</td>
###xml 2401 2421 2272 2292 <tr xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><td rowspan="1" colspan="1">Mock transfection</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">&#8211;</td></tr>
###xml 2111 2421 2049 2292 <tbody xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" align="left"><tr><td rowspan="1" colspan="1">Topo II&#945;</td><td rowspan="1" colspan="1">100</td><td rowspan="1" colspan="1">100</td><td rowspan="1" colspan="1">0.91 &#177; 0.20</td></tr><tr><td rowspan="1" colspan="1">Topo II&#946;</td><td rowspan="1" colspan="1">11.3 &#177; 5.6</td><td rowspan="1" colspan="1">69.8 &#177; 18.1</td><td rowspan="1" colspan="1">0.14 &#177; 0.10</td></tr><tr><td rowspan="1" colspan="1">&#946; NTS/&#945;</td><td rowspan="1" colspan="1">128.6 &#177; 18.2</td><td rowspan="1" colspan="1">73.0 &#177; 11.6</td><td rowspan="1" colspan="1">1.64 &#177; 0.61</td></tr><tr><td rowspan="1" colspan="1">&#945; NTS/&#946;</td><td rowspan="1" colspan="1">5.1 &#177; 3.3</td><td rowspan="1" colspan="1">85.6 &#177; 16.8</td><td rowspan="1" colspan="1">0.11 &#177; 0.05</td></tr><tr><td rowspan="1" colspan="1">&#945;/&#946; CTR</td><td rowspan="1" colspan="1">3.9 &#177; 4.7</td><td rowspan="1" colspan="1">120.9 &#177; 42.1</td><td rowspan="1" colspan="1">0.14 &#177; 0.11</td></tr><tr><td rowspan="1" colspan="1">&#946;/&#945; CTR</td><td rowspan="1" colspan="1">69.5 &#177; 32.2</td><td rowspan="1" colspan="1">71.1 &#177; 13.3</td><td rowspan="1" colspan="1">1.08 &#177; 0.35</td></tr><tr><td rowspan="1" colspan="1">Mock transfection</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">&#8211;</td></tr></tbody>
###xml 2081 2421 2019 2292 <table xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" frame="hsides" rules="groups"><thead align="left"><tr><th rowspan="1" colspan="1">Construct<xref ref-type="table-fn" rid="TF2"><sup>b</sup></xref></th><th rowspan="1" colspan="1">TET<xref ref-type="table-fn" rid="TF3"><sup>c</sup></xref> (%)</th><th rowspan="1" colspan="1">PURO<xref ref-type="table-fn" rid="TF3"><sup>c</sup></xref> (%)</th><th rowspan="1" colspan="1">CI<xref ref-type="table-fn" rid="TF4"><sup>d</sup></xref></th></tr></thead><tbody align="left"><tr><td rowspan="1" colspan="1">Topo II&#945;</td><td rowspan="1" colspan="1">100</td><td rowspan="1" colspan="1">100</td><td rowspan="1" colspan="1">0.91 &#177; 0.20</td></tr><tr><td rowspan="1" colspan="1">Topo II&#946;</td><td rowspan="1" colspan="1">11.3 &#177; 5.6</td><td rowspan="1" colspan="1">69.8 &#177; 18.1</td><td rowspan="1" colspan="1">0.14 &#177; 0.10</td></tr><tr><td rowspan="1" colspan="1">&#946; NTS/&#945;</td><td rowspan="1" colspan="1">128.6 &#177; 18.2</td><td rowspan="1" colspan="1">73.0 &#177; 11.6</td><td rowspan="1" colspan="1">1.64 &#177; 0.61</td></tr><tr><td rowspan="1" colspan="1">&#945; NTS/&#946;</td><td rowspan="1" colspan="1">5.1 &#177; 3.3</td><td rowspan="1" colspan="1">85.6 &#177; 16.8</td><td rowspan="1" colspan="1">0.11 &#177; 0.05</td></tr><tr><td rowspan="1" colspan="1">&#945;/&#946; CTR</td><td rowspan="1" colspan="1">3.9 &#177; 4.7</td><td rowspan="1" colspan="1">120.9 &#177; 42.1</td><td rowspan="1" colspan="1">0.14 &#177; 0.11</td></tr><tr><td rowspan="1" colspan="1">&#946;/&#945; CTR</td><td rowspan="1" colspan="1">69.5 &#177; 32.2</td><td rowspan="1" colspan="1">71.1 &#177; 13.3</td><td rowspan="1" colspan="1">1.08 &#177; 0.35</td></tr><tr><td rowspan="1" colspan="1">Mock transfection</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">&#8211;</td></tr></tbody></table>
###xml 2421 2422 2292 2293 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">a</sup>
###xml 2664 2666 2527 2529 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B26">26</xref>
###xml 2421 2668 2292 2531 <p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" textid="32"><sup>a</sup>HTETOP: human HT-1080 cells in which both alleles of the TOP2&#945; gene are disrupted and which are salvaged by transgenic expression of human topoisomerase II&#945; from a tetracycline repressible construct stably integrated into the genome (<xref ref-type="bibr" rid="B26">26</xref>).</p>
###xml 2421 2668 2292 2531 <fn xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="TF1"><p textid="32"><sup>a</sup>HTETOP: human HT-1080 cells in which both alleles of the TOP2&#945; gene are disrupted and which are salvaged by transgenic expression of human topoisomerase II&#945; from a tetracycline repressible construct stably integrated into the genome (<xref ref-type="bibr" rid="B26">26</xref>).</p></fn>
###xml 2668 2669 2531 2532 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">b</sup>
###xml 2879 2887 2738 2746 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F1">Figure 1</xref>
###xml 2668 2889 2531 2748 <p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" textid="33"><sup>b</sup>Constructs tested for complementation of tetracycline-induced shutdown of heterologous topoisomerase II&#945; expression. All constructs also confer puromycin resistance. For nomenclature of constructs refer to <xref ref-type="fig" rid="F1">Figure 1</xref>B.</p>
###xml 2668 2889 2531 2748 <fn xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="TF2"><p textid="33"><sup>b</sup>Constructs tested for complementation of tetracycline-induced shutdown of heterologous topoisomerase II&#945; expression. All constructs also confer puromycin resistance. For nomenclature of constructs refer to <xref ref-type="fig" rid="F1">Figure 1</xref>B.</p></fn>
###xml 2889 2890 2748 2749 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">c</sup>
###xml 2956 2957 2815 2816 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
###xml 3022 3024 2877 2879 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;1</sup>
###xml 3066 3068 2917 2919 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;1</sup>
###xml 2889 3213 2748 3058 <p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" textid="34"><sup>c</sup>Number of stable cell clones obtained after transfection of 3 &#215; 10<sup>6</sup> HTETOP cells and selection with puromycin (PURO, 0.4&#8201;&#181;g &#183; ml<sup>&#8722;1</sup>,48&#8201;h) or tetracycline (TET, 1&#8201;&#181;g &#183; ml<sup>&#8722;1</sup>, 48&#8201;h). Numbers are normalized to those obtained with topoisomerase II&#945; (row 1). Mean values &#177; SEM of three similar experiments are given.</p>
###xml 2889 3213 2748 3058 <fn xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="TF3"><p textid="34"><sup>c</sup>Number of stable cell clones obtained after transfection of 3 &#215; 10<sup>6</sup> HTETOP cells and selection with puromycin (PURO, 0.4&#8201;&#181;g &#183; ml<sup>&#8722;1</sup>,48&#8201;h) or tetracycline (TET, 1&#8201;&#181;g &#183; ml<sup>&#8722;1</sup>, 48&#8201;h). Numbers are normalized to those obtained with topoisomerase II&#945; (row 1). Mean values &#177; SEM of three similar experiments are given.</p></fn>
###xml 3213 3214 3058 3059 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">d</sup>
###xml 3213 3420 3058 3263 <p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" textid="35"><sup>d</sup>Complementation index: ratio of stable cell clones obtained upon selection with tetracycline versus puromycin. Values are not normalized. Mean values &#177; SEM of at least three similar experiments are given.</p>
###xml 3213 3420 3058 3263 <fn xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="TF4"><p textid="35"><sup>d</sup>Complementation index: ratio of stable cell clones obtained upon selection with tetracycline versus puromycin. Values are not normalized. Mean values &#177; SEM of at least three similar experiments are given.</p></fn>
###xml 2421 3420 2292 3263 <table-wrap-foot xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><fn id="TF1"><p textid="32"><sup>a</sup>HTETOP: human HT-1080 cells in which both alleles of the TOP2&#945; gene are disrupted and which are salvaged by transgenic expression of human topoisomerase II&#945; from a tetracycline repressible construct stably integrated into the genome (<xref ref-type="bibr" rid="B26">26</xref>).</p></fn><fn id="TF2"><p textid="33"><sup>b</sup>Constructs tested for complementation of tetracycline-induced shutdown of heterologous topoisomerase II&#945; expression. All constructs also confer puromycin resistance. For nomenclature of constructs refer to <xref ref-type="fig" rid="F1">Figure 1</xref>B.</p></fn><fn id="TF3"><p textid="34"><sup>c</sup>Number of stable cell clones obtained after transfection of 3 &#215; 10<sup>6</sup> HTETOP cells and selection with puromycin (PURO, 0.4&#8201;&#181;g &#183; ml<sup>&#8722;1</sup>,48&#8201;h) or tetracycline (TET, 1&#8201;&#181;g &#183; ml<sup>&#8722;1</sup>, 48&#8201;h). Numbers are normalized to those obtained with topoisomerase II&#945; (row 1). Mean values &#177; SEM of three similar experiments are given.</p></fn><fn id="TF4"><p textid="35"><sup>d</sup>Complementation index: ratio of stable cell clones obtained upon selection with tetracycline versus puromycin. Values are not normalized. Mean values &#177; SEM of at least three similar experiments are given.</p></fn></table-wrap-foot>
###xml 1989 3420 1941 3263 <table-wrap xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="T1" position="float"><label>Table 1.</label><caption><p textid="31">HTETOP complementation with topoisomerase II&#945;, II&#946; and II&#945;/&#946;-chimeras<xref ref-type="table-fn" rid="TF1"><sup>a</sup></xref></p></caption><table frame="hsides" rules="groups"><thead align="left"><tr><th rowspan="1" colspan="1">Construct<xref ref-type="table-fn" rid="TF2"><sup>b</sup></xref></th><th rowspan="1" colspan="1">TET<xref ref-type="table-fn" rid="TF3"><sup>c</sup></xref> (%)</th><th rowspan="1" colspan="1">PURO<xref ref-type="table-fn" rid="TF3"><sup>c</sup></xref> (%)</th><th rowspan="1" colspan="1">CI<xref ref-type="table-fn" rid="TF4"><sup>d</sup></xref></th></tr></thead><tbody align="left"><tr><td rowspan="1" colspan="1">Topo II&#945;</td><td rowspan="1" colspan="1">100</td><td rowspan="1" colspan="1">100</td><td rowspan="1" colspan="1">0.91 &#177; 0.20</td></tr><tr><td rowspan="1" colspan="1">Topo II&#946;</td><td rowspan="1" colspan="1">11.3 &#177; 5.6</td><td rowspan="1" colspan="1">69.8 &#177; 18.1</td><td rowspan="1" colspan="1">0.14 &#177; 0.10</td></tr><tr><td rowspan="1" colspan="1">&#946; NTS/&#945;</td><td rowspan="1" colspan="1">128.6 &#177; 18.2</td><td rowspan="1" colspan="1">73.0 &#177; 11.6</td><td rowspan="1" colspan="1">1.64 &#177; 0.61</td></tr><tr><td rowspan="1" colspan="1">&#945; NTS/&#946;</td><td rowspan="1" colspan="1">5.1 &#177; 3.3</td><td rowspan="1" colspan="1">85.6 &#177; 16.8</td><td rowspan="1" colspan="1">0.11 &#177; 0.05</td></tr><tr><td rowspan="1" colspan="1">&#945;/&#946; CTR</td><td rowspan="1" colspan="1">3.9 &#177; 4.7</td><td rowspan="1" colspan="1">120.9 &#177; 42.1</td><td rowspan="1" colspan="1">0.14 &#177; 0.11</td></tr><tr><td rowspan="1" colspan="1">&#946;/&#945; CTR</td><td rowspan="1" colspan="1">69.5 &#177; 32.2</td><td rowspan="1" colspan="1">71.1 &#177; 13.3</td><td rowspan="1" colspan="1">1.08 &#177; 0.35</td></tr><tr><td rowspan="1" colspan="1">Mock transfection</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">&#8211;</td></tr></tbody></table><table-wrap-foot><fn id="TF1"><p textid="32"><sup>a</sup>HTETOP: human HT-1080 cells in which both alleles of the TOP2&#945; gene are disrupted and which are salvaged by transgenic expression of human topoisomerase II&#945; from a tetracycline repressible construct stably integrated into the genome (<xref ref-type="bibr" rid="B26">26</xref>).</p></fn><fn id="TF2"><p textid="33"><sup>b</sup>Constructs tested for complementation of tetracycline-induced shutdown of heterologous topoisomerase II&#945; expression. All constructs also confer puromycin resistance. For nomenclature of constructs refer to <xref ref-type="fig" rid="F1">Figure 1</xref>B.</p></fn><fn id="TF3"><p textid="34"><sup>c</sup>Number of stable cell clones obtained after transfection of 3 &#215; 10<sup>6</sup> HTETOP cells and selection with puromycin (PURO, 0.4&#8201;&#181;g &#183; ml<sup>&#8722;1</sup>,48&#8201;h) or tetracycline (TET, 1&#8201;&#181;g &#183; ml<sup>&#8722;1</sup>, 48&#8201;h). Numbers are normalized to those obtained with topoisomerase II&#945; (row 1). Mean values &#177; SEM of three similar experiments are given.</p></fn><fn id="TF4"><p textid="35"><sup>d</sup>Complementation index: ratio of stable cell clones obtained upon selection with tetracycline versus puromycin. Values are not normalized. Mean values &#177; SEM of at least three similar experiments are given.</p></fn></table-wrap-foot></table-wrap>
###xml 286 291 <span type="species:ncbi:9606">human</span>
###xml 1649 1654 <span type="species:ncbi:9606">human</span>
###xml 2430 2435 <span type="species:ncbi:9606">human</span>
###xml 2559 2564 <span type="species:ncbi:9606">human</span>
Our observation that targeting to metaphase chromosomes is promoted by the alpha CTR (Figure 3) suggests that this region may also enable topoisomerase IIalpha to perform its essential functions in proliferating cells. We tested this hypothesis by complementation studies making use of human HT-1080 cells, in which both alleles of the TOP2alpha gene are disrupted and cell proliferation is supported by expression of topoisomerase IIalpha from a tetracycline repressible vector stably integrated into the genome (26). These HTETOP cells, which die when topoisomerase IIalpha is depleted by the addition of tetracycline, were stably transfected with the YFP-fused topoisomerase II constructs investigated here (Figure 1B) and the frequency with which colonies could form in the presence of tetracycline was measured. The results are summarized in Table 1. In the absence of any transfected constructs, no viable cell clones emerged in the presence of tetracycline (row 7), but the YFP-fused version of topoisomerase IIalpha was able to support proliferation of the cells in the presence of tetracycline, as expected (row 1). The YFP-fused version of topoisomerase IIbeta, however, consistently gave rise to a much lower frequency of clones (row 2). Most interestingly, topoisomerase IIalpha lost most of its ability to support cell proliferation upon replacement of its CTR with that of the beta isoform (row 5), whereas topoisomerase IIbeta furnished with the alpha CTR gained this ability (row 6). A similar effect was not observed upon exchanging the non-conserved N-terminal stretches of the isozymes (rows 3 and 4). In summary, all versions of human topoisomerase II bearing the alpha CTR were capable of supporting cell proliferation (rows 1, 3 and 6), whereas all those furnished with the beta CTR (rows 2, 4 and 5) were highly inefficient in this respect. It is, however, important to note that the latter constructs were not completely incapable of supporting cell proliferation. Table 1.HTETOP complementation with topoisomerase IIalpha, IIbeta and IIalpha/beta-chimerasaConstructbTETc (%)PUROc (%)CIdTopo IIalpha1001000.91 +/- 0.20Topo IIbeta11.3 +/- 5.669.8 +/- 18.10.14 +/- 0.10beta NTS/alpha128.6 +/- 18.273.0 +/- 11.61.64 +/- 0.61alpha NTS/beta5.1 +/- 3.385.6 +/- 16.80.11 +/- 0.05alpha/beta CTR3.9 +/- 4.7120.9 +/- 42.10.14 +/- 0.11beta/alpha CTR69.5 +/- 32.271.1 +/- 13.31.08 +/- 0.35Mock transfection00-aHTETOP: human HT-1080 cells in which both alleles of the TOP2alpha gene are disrupted and which are salvaged by transgenic expression of human topoisomerase IIalpha from a tetracycline repressible construct stably integrated into the genome (26).bConstructs tested for complementation of tetracycline-induced shutdown of heterologous topoisomerase IIalpha expression. All constructs also confer puromycin resistance. For nomenclature of constructs refer to Figure 1B.cNumber of stable cell clones obtained after transfection of 3 x 106 HTETOP cells and selection with puromycin (PURO, 0.4 microg . ml-1,48 h) or tetracycline (TET, 1 microg . ml-1, 48 h). Numbers are normalized to those obtained with topoisomerase IIalpha (row 1). Mean values +/- SEM of three similar experiments are given.dComplementation index: ratio of stable cell clones obtained upon selection with tetracycline versus puromycin. Values are not normalized. Mean values +/- SEM of at least three similar experiments are given.
###end p 30
###begin p 31
###xml 83 84 69 70 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">a</sup>
###xml 83 84 69 70 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table-fn" rid="TF1"><sup>a</sup></xref>
HTETOP complementation with topoisomerase IIalpha, IIbeta and IIalpha/beta-chimerasa
###end p 31
###begin p 32
###xml 0 1 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">a</sup>
###xml 243 245 235 237 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B26">26</xref>
###xml 9 14 <span type="species:ncbi:9606">human</span>
###xml 138 143 <span type="species:ncbi:9606">human</span>
aHTETOP: human HT-1080 cells in which both alleles of the TOP2alpha gene are disrupted and which are salvaged by transgenic expression of human topoisomerase IIalpha from a tetracycline repressible construct stably integrated into the genome (26).
###end p 32
###begin p 33
###xml 0 1 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">b</sup>
###xml 211 219 207 215 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F1">Figure 1</xref>
bConstructs tested for complementation of tetracycline-induced shutdown of heterologous topoisomerase IIalpha expression. All constructs also confer puromycin resistance. For nomenclature of constructs refer to Figure 1B.
###end p 33
###begin p 34
###xml 0 1 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">c</sup>
###xml 67 68 67 68 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
###xml 133 135 129 131 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;1</sup>
###xml 177 179 169 171 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;1</sup>
cNumber of stable cell clones obtained after transfection of 3 x 106 HTETOP cells and selection with puromycin (PURO, 0.4 microg . ml-1,48 h) or tetracycline (TET, 1 microg . ml-1, 48 h). Numbers are normalized to those obtained with topoisomerase IIalpha (row 1). Mean values +/- SEM of three similar experiments are given.
###end p 34
###begin p 35
###xml 0 1 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">d</sup>
dComplementation index: ratio of stable cell clones obtained upon selection with tetracycline versus puromycin. Values are not normalized. Mean values +/- SEM of at least three similar experiments are given.
###end p 35
###begin title 36
Support of cell proliferation by topoisomerase IIbeta requires highly elevated enzyme levels
###end title 36
###begin p 37
###xml 98 105 94 101 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T1">Table 1</xref>
###xml 235 242 228 235 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T1">Table 1</xref>
###xml 324 331 317 324 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T1">Table 1</xref>
###xml 1132 1140 1091 1099 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F5">Figure 5</xref>
###xml 1252 1260 1211 1219 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F5">Figure 5</xref>
###xml 1727 1735 1660 1668 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F5">Figure 5</xref>
###xml 1915 1923 1848 1856 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F2">Figure 2</xref>
###xml 2107 2115 2036 2044 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F5">Figure 5</xref>
###xml 2332 2340 2251 2259 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F5">Figure 5</xref>
###xml 2535 2543 2447 2455 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F5">Figure 5</xref>
###xml 3021 3029 2916 2924 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F5">Figure 5</xref>
###xml 3299 3307 3187 3195 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F5">Figure 5</xref>
###xml 3413 3421 3298 3306 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F5">Figure 5</xref>
###xml 3445 3453 3330 3338 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F5">Figure 5</xref>
###xml 3581 3589 3463 3471 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F3">Figure 3</xref>
###xml 4123 4132 3980 3989 <label xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 5.</label>
###xml 4211 4212 4061 4062 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 4729 4730 4565 4566 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
###xml 5035 5036 4851 4852 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</bold>
###xml 5038 5045 4854 4861 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">In vivo</italic>
###xml 4132 5486 3989 5295 <p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" textid="38">Characterization of HTETOP clones rescued by topoisomerase II&#945; or II&#946;. (<bold>A</bold>) Immunoblot analysis of YFP-fused topoisomerase II constructs expressed in HTETOP cells. Whole cell lysates of untransfected HTETOP (lane 1) or tetracycline resistant HTETOP clones expressing topoisomerase II&#945; (lane 2) or topoisomerase II&#946; (lanes 3, 4 and 5) were subjected to SDS PAGE (6% gels) and western blotting. Blots were stained with YFP antibodies (top), or antibodies against human topoisomerase II&#945; (middle), or II&#946; (bottom). Positions of marker proteins are indicated on the right margin. (<bold>B</bold>) Yellow fluorescence level of untransfected HTETOP (HTETOP) or tetracycline resistant HTETOP clones expressing topoisomerase II&#945; (topo II&#945; compl-1) or topoisomerase II&#946; (topo II&#946; compl-1, topo II&#946; compl-2 and topo II&#946; compl-3) was measured by flow cytometry and shown as histograms. (<bold>C</bold>) <italic>In vivo</italic> localization of YFP-fused topoisomerase II constructs in interphase nuclei and during metaphase. Tetracycline resistant HTETOP clones stably expressing topoisomerase II&#945; (row 1) or II&#946; (rows 1, 2 and 3) were visualized by fluorescence microscopy. Corresponding phase contrast images (left) and YFP images (right) are shown. Left and right of image pairs show representative examples of cells at interphase and metaphase respectively.</p>
###xml 4132 5486 3989 5295 <caption xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><p textid="38">Characterization of HTETOP clones rescued by topoisomerase II&#945; or II&#946;. (<bold>A</bold>) Immunoblot analysis of YFP-fused topoisomerase II constructs expressed in HTETOP cells. Whole cell lysates of untransfected HTETOP (lane 1) or tetracycline resistant HTETOP clones expressing topoisomerase II&#945; (lane 2) or topoisomerase II&#946; (lanes 3, 4 and 5) were subjected to SDS PAGE (6% gels) and western blotting. Blots were stained with YFP antibodies (top), or antibodies against human topoisomerase II&#945; (middle), or II&#946; (bottom). Positions of marker proteins are indicated on the right margin. (<bold>B</bold>) Yellow fluorescence level of untransfected HTETOP (HTETOP) or tetracycline resistant HTETOP clones expressing topoisomerase II&#945; (topo II&#945; compl-1) or topoisomerase II&#946; (topo II&#946; compl-1, topo II&#946; compl-2 and topo II&#946; compl-3) was measured by flow cytometry and shown as histograms. (<bold>C</bold>) <italic>In vivo</italic> localization of YFP-fused topoisomerase II constructs in interphase nuclei and during metaphase. Tetracycline resistant HTETOP clones stably expressing topoisomerase II&#945; (row 1) or II&#946; (rows 1, 2 and 3) were visualized by fluorescence microscopy. Corresponding phase contrast images (left) and YFP images (right) are shown. Left and right of image pairs show representative examples of cells at interphase and metaphase respectively.</p></caption>
###xml 5486 5486 5295 5295 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xlink:href="gkm102f5"/>
###xml 4123 5486 3980 5295 <fig xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="F5" position="float"><label>Figure 5.</label><caption><p textid="38">Characterization of HTETOP clones rescued by topoisomerase II&#945; or II&#946;. (<bold>A</bold>) Immunoblot analysis of YFP-fused topoisomerase II constructs expressed in HTETOP cells. Whole cell lysates of untransfected HTETOP (lane 1) or tetracycline resistant HTETOP clones expressing topoisomerase II&#945; (lane 2) or topoisomerase II&#946; (lanes 3, 4 and 5) were subjected to SDS PAGE (6% gels) and western blotting. Blots were stained with YFP antibodies (top), or antibodies against human topoisomerase II&#945; (middle), or II&#946; (bottom). Positions of marker proteins are indicated on the right margin. (<bold>B</bold>) Yellow fluorescence level of untransfected HTETOP (HTETOP) or tetracycline resistant HTETOP clones expressing topoisomerase II&#945; (topo II&#945; compl-1) or topoisomerase II&#946; (topo II&#946; compl-1, topo II&#946; compl-2 and topo II&#946; compl-3) was measured by flow cytometry and shown as histograms. (<bold>C</bold>) <italic>In vivo</italic> localization of YFP-fused topoisomerase II constructs in interphase nuclei and during metaphase. Tetracycline resistant HTETOP clones stably expressing topoisomerase II&#945; (row 1) or II&#946; (rows 1, 2 and 3) were visualized by fluorescence microscopy. Corresponding phase contrast images (left) and YFP images (right) are shown. Left and right of image pairs show representative examples of cells at interphase and metaphase respectively.</p></caption><graphic xlink:href="gkm102f5"/></fig>
###xml 4606 4611 <span type="species:ncbi:9606">human</span>
The average complementation index for all constructs bearing the alpha CTR was 1.21 (derived from Table 1, rows 1, 3 and 6). In contrast, the average complementation index for all constructs bearing the beta CTR was 0.13 (derived from Table 1, rows 2, 4 and 5). Because no viable cell clones emerged from mock transfection (Table 1, row 7), these observations suggest that topoisomerase IIbeta (or enzyme chimeras bearing the beta CTR) can also support cell proliferation to some extent. Two explanations for this result can be considered: (i) topoisomerase IIbeta could be able to substitute for the alpha isoform, when present at much higher levels; (ii) binding sites normally occupied by topoisomerase IIalpha (e.g. sites on mitotic chromosomes) could become freely accessible to the beta isoform when the alpha isoform is absent. These sites could then be occupied by topoisomerase IIbeta irrespective of its concentration in the cell. To investigate these hypotheses, we compared expression levels and localization of YFP-fused topoisomerase IIalpha or IIbeta in clones supporting cell growth in the presence of tetracycline (Figure 5). From comparison of representative cell clones subjected to western blotting and probing with YFP antibodies (Figure 5A, top) it became readily apparent that complementation by YFP-fused topoisomerase IIbeta (lanes 3, 4 and 5) requires much higher expression levels than complementation by YFP-fused topoisomerase IIalpha (lane 2). Flow cytometry confirmed this finding, showing that YFP-fluorescence was approximately10-fold brighter in various cell clones complemented by YFP-fused topoisomerase IIbeta than in a reference cell clone complemented by YFP-fused topoisomerase IIalpha (Figure 5B). Notwithstanding our hesitations about quantitative comparisons between YFP-fused and endogenous topoisomerase II species based on topoisomerase II-directed immunoblotting (see Figure 2B), it should be noted that the cellular complement of YFP-fused topoisomerase IIalpha enabling full cell proliferation was hardly detectable by topoisomerase-directed immunoblotting (Figure 5A, middle, compare lane 1 with lane 2), whereas YFP-fused topoisomerase IIbeta complementing topoisomerase IIalpha function gave a much more intense signal than corresponding bands of endogenous topoisomerase IIbeta (Figure 5A, compare bands within lanes 3, 4 and 5). Thus, in our model system, the beta isoform seems only able to substitute for topoisomerase IIalpha when it is highly (at least 10-fold) overexpressed. Figure 5C further suggests that, upon repression of topoisomerase IIalpha expression, binding sites on mitotic chromosomes normally occupied by this enzyme do not become freely accessible to the beta isoform and are not readily occupied by it. If that were the case, topoisomerase IIbeta should accumulate on metaphase chromosomes upon repression of topoisomerase IIalpha. However, this was clearly not the case in any of the cell clones complemented by YFP-fused topoisomerase IIbeta (Figure 5C, rows 2-4). In all these cell clones, YFP-fused topoisomerase IIbeta was mostly localized in the cytoplasm during mitosis. We failed to detect an accumulation of the enzyme on metaphase chromosomes, as seen in the same cell model with YFP-fused topoisomerase IIalpha (Figure 5C, row 1). It should also be noted that localization of YFP-fused topoisomerase IIbeta during interphase (Figure 5C, left) and metaphase (Figure 5C, right) was identical to that observed in HEK 293 cells where endogenous expression of topoisomerase IIbeta was not silenced (Figure 3A and B). In summary, these morphological data suggest that the binding equilibrium of topoisomerase IIbeta at metaphase chromosomes is (i) independent of the absence or presence of topoisomerase IIalpha, and (ii) not significantly influenced by the total cellular level of topoisomerase IIalpha and IIbeta. Thus, the weak but notable ability of the beta isoform to complement the function of the alpha isoform cannot be due to an increase in its propensity to interact with mitotic chromosomes upon removal of topoisomerase IIalpha. Figure 5.Characterization of HTETOP clones rescued by topoisomerase IIalpha or IIbeta. (A) Immunoblot analysis of YFP-fused topoisomerase II constructs expressed in HTETOP cells. Whole cell lysates of untransfected HTETOP (lane 1) or tetracycline resistant HTETOP clones expressing topoisomerase IIalpha (lane 2) or topoisomerase IIbeta (lanes 3, 4 and 5) were subjected to SDS PAGE (6% gels) and western blotting. Blots were stained with YFP antibodies (top), or antibodies against human topoisomerase IIalpha (middle), or IIbeta (bottom). Positions of marker proteins are indicated on the right margin. (B) Yellow fluorescence level of untransfected HTETOP (HTETOP) or tetracycline resistant HTETOP clones expressing topoisomerase IIalpha (topo IIalpha compl-1) or topoisomerase IIbeta (topo IIbeta compl-1, topo IIbeta compl-2 and topo IIbeta compl-3) was measured by flow cytometry and shown as histograms. (C) In vivo localization of YFP-fused topoisomerase II constructs in interphase nuclei and during metaphase. Tetracycline resistant HTETOP clones stably expressing topoisomerase IIalpha (row 1) or IIbeta (rows 1, 2 and 3) were visualized by fluorescence microscopy. Corresponding phase contrast images (left) and YFP images (right) are shown. Left and right of image pairs show representative examples of cells at interphase and metaphase respectively.
###end p 37
###begin p 38
###xml 79 80 72 73 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 597 598 576 577 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
###xml 903 904 862 863 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</bold>
###xml 906 913 865 872 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">In vivo</italic>
###xml 474 479 <span type="species:ncbi:9606">human</span>
Characterization of HTETOP clones rescued by topoisomerase IIalpha or IIbeta. (A) Immunoblot analysis of YFP-fused topoisomerase II constructs expressed in HTETOP cells. Whole cell lysates of untransfected HTETOP (lane 1) or tetracycline resistant HTETOP clones expressing topoisomerase IIalpha (lane 2) or topoisomerase IIbeta (lanes 3, 4 and 5) were subjected to SDS PAGE (6% gels) and western blotting. Blots were stained with YFP antibodies (top), or antibodies against human topoisomerase IIalpha (middle), or IIbeta (bottom). Positions of marker proteins are indicated on the right margin. (B) Yellow fluorescence level of untransfected HTETOP (HTETOP) or tetracycline resistant HTETOP clones expressing topoisomerase IIalpha (topo IIalpha compl-1) or topoisomerase IIbeta (topo IIbeta compl-1, topo IIbeta compl-2 and topo IIbeta compl-3) was measured by flow cytometry and shown as histograms. (C) In vivo localization of YFP-fused topoisomerase II constructs in interphase nuclei and during metaphase. Tetracycline resistant HTETOP clones stably expressing topoisomerase IIalpha (row 1) or IIbeta (rows 1, 2 and 3) were visualized by fluorescence microscopy. Corresponding phase contrast images (left) and YFP images (right) are shown. Left and right of image pairs show representative examples of cells at interphase and metaphase respectively.
###end p 38
###begin title 39
DISCUSSION
###end title 39
###begin p 40
###xml 151 153 151 153 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B55">55</xref>
###xml 154 156 154 156 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B61">61</xref>
###xml 376 378 376 378 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B55">55</xref>
###xml 379 381 379 381 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B62">62</xref>
###xml 382 384 382 384 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B63">63</xref>
###xml 443 445 443 445 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B38">38</xref>
###xml 560 562 560 562 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B16">16</xref>
###xml 662 669 662 669 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 671 673 671 673 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B39">39</xref>
###xml 59 64 <span type="species:ncbi:4932">yeast</span>
###xml 69 74 <span type="species:ncbi:9606">human</span>
It is well established that the C-terminal domains of both yeast and human topoisomerase II are dispensable for the enzyme's basic catalytic activity (55,61). On the other hand, a large body of evidence suggests that the C-terminal domain plays a role in regulating the cellular functioning of topoisomerase II. Most notably, it contains crucial nuclear localization signals (55,62,63) and sites phosphorylated in a cell-cycle-related manner (38). Since the C-terminal domains are the most divergent portions of the two mammalian isoforms of topoisomerase II (16), it has been proposed that they determine specific functions differing between these two isoforms in vivo (39). Here, we provide direct evidence in support of this view. We demonstrate that the divergent CTRs of topoisomerase IIalpha and IIbeta govern two features in which the two isoforms characteristically differ, namely binding to mitotic chromosomes and support of cell proliferation. We show that YFP-fused topoisomerase IIalpha is preferentially chromosome-bound during mitosis and fully supports proliferation of cells lacking endogenous topoisomerase IIalpha. In contrast, the majority of YFP-fused topoisomerase IIbeta is not chromosome-bound at mitosis, and clones emerged from complementation experiments at greatly reduced frequencies. The specific features of the alpha isoform were stringently linked to the presence of the alpha CTR. Replacement of the CTR in topoisomerase IIbeta with the alpha CTR produced an enzyme chimera that behaved like topoisomerase IIalpha, whereas the converse experiment produced an enzyme chimera behaving like topoisomerase IIbeta.
###end p 40
###begin p 41
###xml 214 216 207 209 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B25">25</xref>
###xml 381 383 370 372 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B26">26</xref>
###xml 384 386 373 375 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B27">27</xref>
###xml 387 389 376 378 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B64">64</xref>
###xml 891 893 868 870 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B65">65</xref>
###xml 894 896 871 873 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B66">66</xref>
###xml 956 958 933 935 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B67">67</xref>
###xml 970 972 947 949 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B68">68</xref>
The requirement of topoisomerase IIalpha for proper cell division has been suggested by indirect evidence showing an essential role in chromosome segregation, which is not readily adopted by the beta-isoform (e.g. 25). More recently, depletion of topoisomerase IIalpha by various experimental strategies resulted in each case in an impaired separation of chromosomes in anaphase. (26,27,64). Here we describe a striking coincidence between the ability of all versions of topoisomerase II furnished with the alpha CTR to complement such a lack of endogenous topoisomerase IIalpha and the propensity of the complementing construct to bind to mitotic chromosomes. We even observe that the alpha CTR alone preferentially binds to metaphase chromosomes. It remains unclear whether chromosome binding is due to direct DNA-interactions, as suggested for various prokaryotic type II topoisomerases (65,66), or to interactions with other proteins, e.g. condensins (67) or HSP90 (68). However, the strict correlation between the binding to metaphase chromosomes and the support of cell proliferation suggests a mechanistic connection between the two. It can be hypothesized (i) that efficient separation of sister chromatids and proper cell division depend on a high, local concentration of active topoisomerase II at the mitotic chromosome, (ii) that under physiological conditions only the alpha isoform accumulates in sufficient concentrations at the mitotic chromosome, and (iii) that this feature is promoted by an intrinsic ability of the alpha CTR to bind to metaphase chromosomes. These hypotheses would assign to the alpha CTR the function of an adaptor that shifts the binding equilibrium of the entire enzyme molecule towards the bound state and thus provides the chromosome at mitosis with sufficient topoisomerase II activity to perform extensive DNA-decatenation in the course of sister chromatid segregation. Our finding that topoisomerase IIbeta can also support cell proliferation when expressed at extremely high levels supports such a hypothesis: sufficient local concentration of active topoisomerase II at the mitotic chromosome cannot only be acquired by expressing normal levels of an enzyme having a high affinity (due to the alpha CTR), but also by expressing highly increased levels of an enzyme having a much lower one (due to the beta CTR).
###end p 41
###begin p 42
###xml 218 220 214 216 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B22">22</xref>
###xml 221 223 217 219 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B23">23</xref>
###xml 531 533 520 522 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B57">57</xref>
###xml 721 723 710 712 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B69">69</xref>
###xml 94 99 <span type="species:ncbi:4932">yeast</span>
###xml 203 208 <span type="species:ncbi:4932">yeast</span>
###xml 256 261 <span type="species:ncbi:4932">yeast</span>
###xml 376 381 <span type="species:ncbi:10090">mouse</span>
###xml 439 444 <span type="species:ncbi:4932">yeast</span>
###xml 512 517 <span type="species:ncbi:4932">yeast</span>
###xml 570 575 <span type="species:ncbi:4932">yeast</span>
###xml 647 652 <span type="species:ncbi:9606">human</span>
###xml 774 779 <span type="species:ncbi:4932">yeast</span>
###xml 1002 1007 <span type="species:ncbi:9606">human</span>
The above interpretation is more difficult to fit with complementation studies carried out in yeast that show that both mammalian isoforms are equally capable of rescuing temperature-sensitive Deltatop2 yeast mutants (22,23). One explanation could be that yeast might be unable to discriminate between the two mammalian isoforms. However, this explanation is unlikely because mouse topoisomerase IIalpha and IIbeta can be discriminated by yeast, in as much as they are distributed in a distinguishable manner in yeast cell nuclei (57). Another explanation could be that yeast is more tolerant to changes in topoisomerase II expression levels than human cells, which are readily killed by overexpression of these enzymes (69). Since high copy number vectors were used in the yeast studies for expression of the complementing enzymes, expression levels of the beta isoform could have been high enough to enable efficient complementation of topoisomerase II functions in the same manner as seen here in a human cell line.
###end p 42
###begin p 43
###xml 237 239 233 235 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B70">70</xref>
###xml 488 490 484 486 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B71">71</xref>
###xml 635 637 624 626 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B17">17</xref>
###xml 743 745 732 734 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B72">72</xref>
###xml 1048 1050 1022 1024 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B73">73</xref>
###xml 1329 1331 1292 1294 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B26">26</xref>
###xml 1343 1345 1306 1308 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B27">27</xref>
###xml 2092 2094 2039 2041 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B72">72</xref>
###xml 143 148 <span type="species:ncbi:4932">yeast</span>
###xml 385 390 <span type="species:ncbi:4932">yeast</span>
###xml 883 890 <span type="species:ncbi:9031">chicken</span>
###xml 1316 1321 <span type="species:ncbi:9606">human</span>
###xml 1337 1341 <span type="species:ncbi:10090">mice</span>
Another possible interpretation of our data is that the topoisomerase IIalpha plays an essential role during replication. It has been shown in yeast that topoisomerase II is required for DNA replication, when topoisomerase I is lacking (70), because movement of DNA replication complexes through the DNA double helix induces positive supercoils ahead of this machinery. Recent work in yeast demonstrates that topoisomerase II relaxes chromatin even more efficiently than topoisomerase I (71). In mammals, topoisomerase IIalpha, but not IIbeta, appears to be a key player in removal of this type of torsional stress during replication (17), and it was postulated that this isoform-specificity is determined by the divergent C-terminal regions (72). The residues that were suggested to play this role in replication are all within the alpha CTRs analyzed here. In addition, a study in chicken fibroblast showed that topoisomerase IIalpha, but not IIbeta, co-localizes with sites of replication, and this targeting was also mediated by the alpha CTR (73). Unfortunately, it is difficult to determine whether topoisomerase IIalpha plays a truly essential role during replication that cannot be complemented by other proteins (e.g. topoisomerase I or topoisomerase IIbeta). Although silencing of topoisomerase IIalpha in human cells (26) and mice (27) causes a defect in chromosome segregation, suggesting that its essential role is during mitosis rather than S-phase, this phenotype could conceivably be caused by loss of an essential topoisomerase IIalpha function during the late phases of replication. Lack of such a function could still allow for a progression into metaphase followed by mitotic catastrophes due to unresolved DNA catenanes. Thus, an essential role of topoisomerase IIalpha in relaxation of positive supercoils generated at late stages of replication cannot be excluded, and our observation that the alpha CTR is required for efficient support of cell proliferation by topoisomerase II may just as well reflect a specific involvement of the alpha isoform in DNA replication (72).
###end p 43
###begin p 44
Regardless of the exact role of the alpha CTR, we demonstrate in this article that it confers a unique, proliferation-associated functionality to the topoisomerase II core enzyme (either version of it), whereas the beta CTR is much less efficient in this respect. It is therefore plausible that the two versions of the CTR cooperate in differential targeting of topoisomerase IIalpha and IIbeta, thus providing unique functionality of the two isoforms in proliferating cells.
###end p 44
###begin title 45
ACKNOWLEDGEMENTS
###end title 45
###begin p 46
This work was supported by the Deutsche Forschungsgemeinschaft (grants BO 910/3-2; SFB 503, GRK 1033) and the Cancer Research UK (grant C9700/A5962). Funding to pay the Open Access publication charge was provided by the above mentioned grants
###end p 46
###begin p 47
###xml 0 30 0 30 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Conflict of interest statement</italic>
Conflict of interest statement. None declared.
###end p 47
###begin title 48
REFERENCES
###end title 48
###begin article-title 49
###xml 91 99 <span type="species:ncbi:4896">S. pombe</span>
DNA topoisomerase II is required for condensation and separation of mitotic chromosomes in S. pombe
###end article-title 49
###begin article-title 50
###xml 59 64 <span type="species:ncbi:4932">yeast</span>
DNA topoisomerase II is required at the time of mitosis in yeast
###end article-title 50
###begin article-title 51
###xml 118 122 <span type="species:ncbi:10633?0.9966199903428296">SV40</span>
Arrest of segregation leads to accumulation of highly intertwined catenated dimers: dissection of the final stages of SV40 DNA replication
###end article-title 51
###begin article-title 52
DNA topoisomerase poisons as antitumor drugs
###end article-title 52
###begin article-title 53
The response of eukaryotic topoisomerases to DNA damage
###end article-title 53
###begin article-title 54
###xml 45 50 <span type="species:ncbi:9606">human</span>
Enhanced processing of UVA-irradiated DNA by human topoisomerase II in living cells
###end article-title 54
###begin article-title 55
Flavonoids as DNA topoisomerase antagonists and poisons: structure-activity relationships
###end article-title 55
###begin article-title 56
Induction of mammalian topoisomerase II dependent DNA cleavage by nonintercalative flavonoids, genistein and orobol
###end article-title 56
###begin article-title 57
###xml 76 82 <span type="species:ncbi:9606">infant</span>
Dietary bioflavonoids induce cleavage in the MLL gene and may contribute to infant leukemia
###end article-title 57
###begin article-title 58
Purification of topoisomerase II from amsacrine-resistant P388 leukemia cells. Evidence for two forms of the enzyme
###end article-title 58
###begin article-title 59
###xml 40 45 <span type="species:ncbi:9606">human</span>
Cloning and sequencing of cDNA encoding human DNA topoisomerase II and localization of the gene to chromosome region 17q21-22
###end article-title 59
###begin article-title 60
###xml 78 83 <span type="species:ncbi:9606">human</span>
Characterization and immunological identification of cDNA clones encoding two human DNA topoisomerase II isozymes
###end article-title 60
###begin article-title 61
###xml 36 41 <span type="species:ncbi:9606">human</span>
Isolation and characterization of a human cDNA clone encoding a novel DNA topoisomerase II homologue from HeLa cells
###end article-title 61
###begin article-title 62
###xml 88 93 <span type="species:ncbi:9606">human</span>
Topoisomerase II alpha and topoisomerase II beta genes: characterization and mapping to human chromosomes 17 and 3, respectively
###end article-title 62
###begin article-title 63
Novel HeLa topoisomerase II is the II beta isoform: complete coding sequence and homology with other type II topoisomerases
###end article-title 63
###begin article-title 64
###xml 54 59 <span type="species:ncbi:9606">human</span>
Isolation of cDNA clones encoding the beta isozyme of human DNA topoisomerase II and localisation of the gene to chromosome 3p24
###end article-title 64
###begin article-title 65
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human topoisomerase IIalpha rapidly relaxes positively supercoiled DNA: implications for enzyme action ahead of replication forks
###end article-title 65
###begin article-title 66
Biochemical and pharmacological properties of p170 and p180 forms of topoisomerase II
###end article-title 66
###begin article-title 67
###xml 45 50 <span type="species:ncbi:9606">human</span>
Drug sensitivity and sequence specificity of human recombinant DNA topoisomerases IIalpha (p170) and IIbeta (p180)
###end article-title 67
###begin article-title 68
###xml 20 25 <span type="species:ncbi:9606">human</span>
Kinetic analysis of human topoisomerase IIalpha and beta DNA binding by surface plasmon resonance
###end article-title 68
###begin article-title 69
###xml 62 67 <span type="species:ncbi:9606">human</span>
Amsacrine-promoted DNA cleavage site determinants for the two human DNA topoisomerase II isoforms alpha and beta
###end article-title 69
###begin article-title 70
###xml 71 95 <span type="species:ncbi:4932">Saccharomyces cerevisiae</span>
###xml 101 106 <span type="species:ncbi:9606">human</span>
###xml 183 188 <span type="species:ncbi:4932">yeast</span>
Complementation of temperature-sensitive topoisomerase II mutations in Saccharomyces cerevisiae by a human TOP2 beta construct allows the study of topoisomerase II beta inhibitors in yeast
###end article-title 70
###begin article-title 71
###xml 0 5 <span type="species:ncbi:9606">Human</span>
###xml 76 81 <span type="species:ncbi:4932">yeast</span>
Human DNA topoisomerases IIalpha and IIbeta can functionally substitute for yeast TOP2 in chromosome segregation and recombination
###end article-title 71
###begin article-title 72
Cellular roles of dna topoisomerases: a molecular perspective
###end article-title 72
###begin article-title 73
###xml 100 105 <span type="species:ncbi:9606">human</span>
Essential mitotic functions of DNA topoisomerase IIalpha are not adopted by topoisomerase IIbeta in human H69 cells
###end article-title 73
###begin article-title 74
###xml 109 114 <span type="species:ncbi:9606">human</span>
Construction, characterization, and complementation of a conditional-lethal DNA topoisomerase IIalpha mutant human cell line
###end article-title 74
###begin article-title 75
Enforced cytokinesis without complete nuclear division in embryonic cells depleting the activity of DNA topoisomerase IIalpha
###end article-title 75
###begin article-title 76
###xml 0 6 <span type="species:ncbi:10090">Murine</span>
Murine transgenic cells lacking DNA topoisomerase IIbeta are resistant to acridines and mitoxantrone: analysis of cytotoxicity and cleavable complex formation
###end article-title 76
###begin article-title 77
###xml 50 65 <span type="species:ncbi:10029">Chinese hamster</span>
Expression of topoisomerases II alpha and beta in Chinese hamster lung cells resistant to topoisomerase II inhibitors
###end article-title 77
###begin article-title 78
###xml 78 93 <span type="species:ncbi:10029">Chinese hamster</span>
Role of topoisomerase II beta in the resistance of 9-OH-ellipticine-resistant Chinese hamster fibroblasts to topoisomerase II inhibitors
###end article-title 78
###begin article-title 79
DNA topoisomerase IIbeta and neural development
###end article-title 79
###begin article-title 80
###xml 46 51 <span type="species:ncbi:10090">mouse</span>
Aberrant lamination in the cerebral cortex of mouse embryos lacking DNA topoisomerase IIbeta
###end article-title 80
###begin article-title 81
Role of topoisomerase IIbeta in the expression of developmentally regulated genes
###end article-title 81
###begin article-title 82
A topoisomerase IIbeta-mediated dsDNA break required for regulated transcription
###end article-title 82
###begin article-title 83
###xml 101 106 <span type="species:ncbi:9606">human</span>
The distribution and expression of the two isoforms of DNA topoisomerase II in normal and neoplastic human tissues
###end article-title 83
###begin article-title 84
###xml 65 70 <span type="species:ncbi:9606">human</span>
Cloning and characterization of the 5'-flanking sequence for the human DNA topoisomerase IIbeta gene
###end article-title 84
###begin article-title 85
###xml 18 23 <span type="species:ncbi:9606">human</span>
Regulation of the human topoisomerase IIalpha gene promoter in confluence-arrested cells
###end article-title 85
###begin article-title 86
Physiological regulation of eukaryotic topoisomerase II
###end article-title 86
###begin article-title 87
Eukaryotic DNA topoisomerase II beta
###end article-title 87
###begin article-title 88
###xml 45 50 <span type="species:ncbi:4932">yeast</span>
Proteolysis patterns of epitopically labeled yeast DNA topoisomerase II suggest an allosteric transition in the enzyme induced by ATP binding
###end article-title 88
###begin article-title 89
###xml 80 85 <span type="species:ncbi:9606">human</span>
Expression, domain structure, and enzymatic properties of an active recombinant human DNA topoisomerase II beta
###end article-title 89
###begin article-title 90
Structure and mechanism of DNA topoisomerase II
###end article-title 90
###begin article-title 91
Cell cycle-coupled relocation of types I and II topoisomerases and modulation of catalytic enzyme activities
###end article-title 91
###begin article-title 92
###xml 12 17 <span type="species:ncbi:9606">human</span>
Dynamics of human DNA topoisomerases IIalpha and IIbeta in living cells
###end article-title 92
###begin article-title 93
CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice
###end article-title 93
###begin article-title 94
Engineering hybrid genes without the use of restriction enzymes: gene splicing by overlap extension
###end article-title 94
###begin article-title 95
Stabilized, long-term expression of heterodimeric proteins from tricistronic mRNA
###end article-title 95
###begin article-title 96
###xml 20 25 <span type="species:ncbi:9606">human</span>
Residues 190-210 of human topoisomerase I are required for enzyme activity in vivo but not in vitro
###end article-title 96
###begin article-title 97
Proliferation-associated nuclear antigen Ki-S1 is identical with topoisomerase IIalpha. Delineation of a carboxyterminal epitope with peptide antibodies
###end article-title 97
###begin article-title 98
Analysis of M phase-specific phosphorylation of DNA topoisomerase II
###end article-title 98
###begin article-title 99
DNA topoisomerases: structure, function, and mechanism
###end article-title 99
###begin article-title 100
###xml 0 15 <span type="species:ncbi:10507">Chlorella virus</span>
###xml 92 107 <span type="species:ncbi:10507">Chlorella virus</span>
Chlorella virus Marburg topoisomerase II: high DNA cleavage activity as a characteristic of Chlorella virus type II enzymes
###end article-title 100
###begin article-title 101
###xml 93 98 <span type="species:ncbi:9606">human</span>
Impact of the C-terminal domain of topoisomerase IIalpha on the DNA cleavage activity of the human enzyme
###end article-title 101
###begin article-title 102
###xml 22 44 <span type="species:ncbi:10506">Chlorella virus PBCV-1</span>
Topoisomerase II from Chlorella virus PBCV-1. Characterization of the smallest known type II topoisomerase
###end article-title 102
###begin article-title 103
###xml 72 78 <span type="species:ncbi:9606">humans</span>
###xml 83 107 <span type="species:ncbi:4932">saccharomyces cerevisiae</span>
Analysis of functional domain organization in DNA topoisomerase II from humans and saccharomyces cerevisiae
###end article-title 103
###begin article-title 104
###xml 77 82 <span type="species:ncbi:9606">human</span>
Using a biochemical approach to identify the primary dimerization regions in human DNA topoisomerase IIalpha
###end article-title 104
###begin article-title 105
Cellular distribution of mammalian DNA topoisomerase II is determined by its catalytically dispensable C-terminal domain
###end article-title 105
###begin article-title 106
###xml 31 55 <span type="species:ncbi:4932">Saccharomyces cerevisiae</span>
Type II DNA topoisomerase from Saccharomyces cerevisiae is a stable dimer
###end article-title 106
###begin article-title 107
Topoisomerase II forms multimers in vitro: effects of metals, beta-glycerophosphate, and phosphorylation of its C-terminal domain
###end article-title 107
###begin article-title 108
###xml 36 41 <span type="species:ncbi:9606">human</span>
Active heterodimers are formed from human DNA topoisomerase II alpha and II beta isoforms
###end article-title 108
###begin article-title 109
###xml 41 54 <span type="species:ncbi:4896">fission yeast</span>
A functional 125-kDa core polypeptide of fission yeast DNA topoisomerase II
###end article-title 109
###begin article-title 110
###xml 25 49 <span type="species:ncbi:4932">Saccharomyces cerevisiae</span>
The C-terminal domain of Saccharomyces cerevisiae DNA topoisomerase II
###end article-title 110
###begin article-title 111
###xml 80 85 <span type="species:ncbi:9606">human</span>
Sequence determinants of nuclear localization in the alpha and beta isoforms of human topoisomerase II
###end article-title 111
###begin article-title 112
Functional compatibility between isoform alpha and beta of type II DNA topoisomerase
###end article-title 112
###begin article-title 113
Structure of the topoisomerase IV C-terminal domain: a broken beta-propeller implies a role as geometry facilitator in catalysis
###end article-title 113
###begin article-title 114
C-terminal domain of gyrase A is predicted to have a beta-propeller structure
###end article-title 114
###begin article-title 115
A role of topoisomerase II in linking DNA replication to chromosome condensation
###end article-title 115
###begin article-title 116
Inhibition of Hsp90 acts synergistically with topoisomerase II poisons to increase the apoptotic killing of cells due to an increase in topoisomerase II mediated DNA damage
###end article-title 116
###begin article-title 117
Induction of apoptosis by deregulated expression of DNA topoisomerase IIalpha
###end article-title 117
###begin article-title 118
###xml 57 81 <span type="species:ncbi:4932">Saccharomyces cerevisiae</span>
Function of DNA topoisomerases as replication swivels in Saccharomyces cerevisiae
###end article-title 118
###begin article-title 119
Topoisomerase II, not topoisomerase I, is the proficient relaxase of nucleosomal DNA
###end article-title 119
###begin article-title 120
Ability of viral topoisomerase II to discern the handedness of supercoiled DNA: bimodal recognition of DNA geometry by type II enzymes
###end article-title 120
###begin article-title 121
###xml 19 26 <span type="species:ncbi:9031">chicken</span>
Co-localization of chicken DNA topoisomerase IIalpha, but not beta, with sites of DNA replication and possible involvement of a C-terminal region of alpha through its binding to PCNA
###end article-title 121

